Details of the Drug

General Information of Drug (ID: DMP6G8T)

• Drug Name: Topotecan
• Synonyms: Hycamptamine; Hycamptin; Hycamtamine; Topotecane; Topotecanum; Topotecan lactone; SKF 104864; SKF-S 104864; TOPOTECAN, HYCAMTIN; Topotecan (BAN); Topotecan [INN:BAN]; Topotecane [INN-French]; Topotecanum [INN-Latin]; Topotecan Monohydrochloride, (S)-Isomer; (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione; (S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; 9-Dimethylaminomethyl-10-hydroxycamptothecin

Indication

Disease Entry	ICD 11	Status	REF
Central nervous system neoplasm	N.A.	Approved	[1]
Cervical cancer	2C77.0	Approved	[1]
Epithelial ovarian cancer	2B5D	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Ovarian cancer	2C73	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Small-cell lung cancer	2C25.Y	Phase 1	[4]
Neuroblastoma	2D11.2	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01CE01: Topotecan
  L01CE: Topoisomerase 1 (TOP1) inhibitors
  L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 421.4
  Logarithm of the Partition Coefficient (xlogp); 0.5
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 13 mL/min/kg [6]
  Elimination: 40% of drug is excreted from urine in the unchanged form [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.1572 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.65% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.8 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 1 mg/mL [5]
• Chemical Identifiers:
  Formula: C23H23N3O5
  IUPAC Name: (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
  Canonical SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
  InChI: InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
  InChIKey: UCFGDBYHRUNTLO-QHCPKHFHSA-N
• Cross-matching ID:
  PubChem CID: 60700
  ChEBI ID: CHEBI:63632
  CAS Number: 123948-87-8
  UNII: 7M7YKX2N15
  DrugBank ID: DB01030
  TTD ID: D02PMO
  VARIDT ID: DR00044
  ACDINA ID: D00690
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Modulator	[8]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[9]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[10]
Multidrug and toxin extrusion protein 2 (SLC47A2)	DT3TX4H	S47A2_HUMAN	Substrate	[11]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[11]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[12]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial (BCKDHA)	OT0LHOZB	ODBA_HUMAN	Drug Response	[14]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1)	OTQRET2B	S5A1_HUMAN	Drug Response	[14]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1)	OTTLJH8W	ATS1_HUMAN	Drug Response	[14]
Acetyl-CoA acetyltransferase, cytosolic (ACAT2)	OTZ092ZJ	THIC_HUMAN	Drug Response	[14]
Acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A)	OTRHPFO2	AN32A_HUMAN	Drug Response	[14]
Actin, gamma-enteric smooth muscle (ACTG2)	OTRDWUO0	ACTH_HUMAN	Drug Response	[14]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Drug Response	[14]
Ankycorbin (RAI14)	OT6USGBK	RAI14_HUMAN	Drug Response	[14]
Ankyrin repeat domain-containing protein 10 (ANKRD10)	OTIZ2VK8	ANR10_HUMAN	Drug Response	[14]
AP-5 complex subunit mu-1 (AP5M1)	OTDLWEBL	AP5M1_HUMAN	Drug Response	[14]

Molecular Expression Atlas of This Drug

• The Studied Disease: Central nervous system neoplasm

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
DNA topoisomerase I (TOP1)	DTT	TOP1	1.05E-01	0.17	0.27
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTP	MATE1	4.58E-22	-5.44E-01	-9.06E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.61E-73	-1.15E+00	-1.66E+00
Multidrug resistance-associated protein 1 (ABCC1)	DTP	MRP1	1.33E-51	5.67E-01	1.25E+00
Breast cancer resistance protein (ABCG2)	DTP	BCRP	1.46E-65	-1.41E+00	-1.41E+00
Multidrug resistance-associated protein 4 (ABCC4)	DTP	MRP4	6.84E-05	8.79E-02	1.77E-01
Multidrug and toxin extrusion protein 2 (SLC47A2)	DTP	MATE2	6.25E-01	-5.97E-03	-1.97E-02

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC2	0.9481	3.4129	0.098	11.4435
SK-ES-1	GDSC2; CTRP2; CCLE	-6.3348	-4.5274	-6.3348	82.2524
ES7	GDSC2	-5.6221	-3.3458	-5.6241	71.6323
HuO9	GDSC2	-4.931	-0.4791	-5.0873	62.7834
EW-22	GDSC2	-4.7589	-2.3929	-4.7649	63.3234
A-673	GDSC2; CTRP2; CCLE	-4.6228	-2.0756	-4.623	70.8868
ES8	GDSC2	-4.5743	-2.2805	-4.58	61.5676
SK-N-MC	CTRP2	-4.3469	-3.8778	-4.3469	67.0319
EW-3	GDSC2	-4.2628	4.5494	-5.7953	54.7795
CADO-ES1	GDSC2; CTRP2	-4.1965	-2.6848	-4.1965	68.2218
EW-16	GDSC2	-4.1398	-0.3427	-4.2613	56.6385
MHH-ES-1	GDSC2; CTRP2; CCLE	-4.0553	-1.443	-4.0558	67.1612
TC71	CTRP2	-4.0089	-1.5737	-4.0092	66.8938
SK-PN-DW	GDSC2	-3.9224	-2.734	-3.9224	55.2653
EW-1	GDSC2	-3.5856	-0.9482	-3.6175	51.828
TC-71	GDSC2; CCLE	-3.5339	-1.4729	-3.5356	56.0872
EW-11	GDSC2	-3.4611	1.3384	-3.8566	50.5193
NY	GDSC2	-2.8886	1.3836	-3.2437	45.6306
SaOS-2	GDSC2; CTRP2; CCLE	-2.3208	1.6139	-2.354	55.5527
EW-24	GDSC2	-1.9386	2.1457	-2.427	37.3964
EW-7	GDSC2	-1.9276	1.0226	-2.1108	36.0901
EW-13	GDSC2	-1.3199	10.0209	-5.2448	40.7511
HOS	GDSC2; CTRP2; CCLE	-0.508	2.64	-0.5373	43.7251
MG-63	GDSC2; CTRP2; CCLE	-0.4721	3.1435	-0.5336	43.5579
CAL-72	GDSC2	-0.4588	4.4531	-1.7749	27.4317
SJSA-1	CTRP2; CCLE	-0.0819	7.3697	-1.0451	42.6613
ES4	GDSC2	0.1804	4.9197	-1.3604	22.7732
CAL-78	GDSC2; CTRP2; CCLE	0.3208	3.7214	0.2459	38.3584
U2OS	GDSC2; CTRP2; CCLE	0.5074	3.503	0.4612	37.0345
Hs 888.T	CTRP2	0.5124	8.2548	-0.7135	39.75
ES6	GDSC2	0.8545	6.4886	-1.4994	21.0688
H-EMC-SS	GDSC2	0.8715	7.1679	-1.8213	22.6173
ES5	GDSC2	1.0443	5.2383	-0.7098	16.0444
EW-18	GDSC2	1.3867	3.2486	0.5826	6.9475
HuO-3N1	GDSC2	1.5542	8.6839	-1.9902	21.2358
SW1353	CTRP2; CCLE	1.7644	5.4804	1.5146	29.3571
CHSA8926	GDSC2	2.3599	11.4146	-2.6999	22.0134
G-292 clone A141B1	GDSC2; CTRP2	3.2199	11.9947	0.4799	28.2507
NOS-1 [Human HNSCC]	GDSC2	3.4659	9.6737	-1.0195	11.3321
Hs 822.T	CTRP2	7.3644	14.11	3.0518	10.1493

Cancer Drug Sensitivity Data Curated from 209 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	-4.6061	-1.928	-4.6065	70.7323
MEC1	CTRP2	-3.1293	0.8402	-3.1517	60.7245
JM1	CTRP2	-6.4245	-4.0271	-6.4245	82.3943
SU-DHL-5	GDSC2	-7.2882	-6.6146	-7.2882	88.9571
OCI-Ly3	CTRP2	-6.9624	-3.7335	-6.9628	84.4242
RS4;11	GDSC2; CTRP2	-6.6803	-4.3477	-6.6803	83.9967
DND-41	GDSC2; CTRP2	-6.584	-4.1303	-6.584	83.299
ALL-SIL	GDSC2; CTRP2; CCLE	-6.4601	-4.3782	-6.4601	82.8736
MOLT-16	GDSC2; CTRP2; CCLE	-6.4335	-3.8958	-6.4335	82.3153
OCI-Ly19	CTRP2	-6.4309	-3.0738	-6.4317	81.3416
CML-T1	GDSC2; CTRP2	-6.4084	-5.1093	-6.4084	82.9105
Ri-1	CTRP2	-6.3101	-0.9377	-6.3412	77.6741
NU-DHL-1	CTRP2	-6.3049	-2.409	-6.3082	79.9062
MHH-CALL-4	CTRP2	-6.2076	-1.774	-6.2169	78.6034
Karpas-231	GDSC2	-6.2013	-4.9101	-6.2013	77.9933
SEM	CTRP2	-6.138	-4.5416	-6.138	81.0628
NU-DUL-1	CTRP2	-5.9821	-3.5873	-5.9821	79.6668
KMS-34	CTRP2; CCLE	-5.8129	-3.7637	-5.8129	78.7871
SU-DHL-8	GDSC2; CTRP2; CCLE	-5.7774	-4.4108	-5.7774	78.7338
BV-173	CTRP2	-5.6344	-4.0837	-5.6344	77.764
MV4-11	CTRP2	-5.5446	-3.5423	-5.5446	77.0672
DEL	GDSC2; CTRP2; CCLE	-5.5154	-4.5205	-5.5154	77.0116
SU-DHL-1	CTRP2	-5.5095	-3.9075	-5.5095	76.9317
JeKo-1	CTRP2	-5.4921	-1.4518	-5.499	75.1556
JSC-1	GDSC2	-5.4609	-3.6869	-5.4612	70.4923
SUP-T1	GDSC2; CTRP2; CCLE	-5.4464	0.5396	-5.5255	72.4124
KY821	GDSC2	-5.4257	-4.0959	-5.4257	70.307
MOLT-13	GDSC2; CTRP2	-5.3706	-2.3715	-5.3712	75.4199
AML-193	CTRP2	-5.3488	-3.3272	-5.3488	75.7842
Hs 445	GDSC2	-5.3057	-1.4143	-5.3766	66.6228
KYO-1	CTRP2	-5.1971	-3.2792	-5.1971	74.8154
HD-MY-Z	CTRP2; CCLE	-5.1883	-1.3888	-5.1935	73.6226
KE-97	CTRP2; CCLE	-5.1648	-2.5455	-5.165	74.3568
MHH-CALL-2	GDSC2	-5.1512	-3.3038	-5.1517	67.4211
JVM-3	GDSC2; CTRP2; CCLE	-5.1034	-3.0622	-5.1034	74.1719
MOLM-16	CTRP2	-5.0844	-1.0348	-5.0932	72.7603
P32/ISH	GDSC2	-5.0044	-3.6537	-5.0045	66.1
P12-Ichikawa	GDSC2; CTRP2; CCLE	-4.969	-3.681	-4.969	73.3683
RPMI-8402	CTRP2; CCLE	-4.963	-3.0986	-4.963	73.2829
TALL-1 [Human adult T-ALL]	CTRP2	-4.8873	4.4364	-5.4882	65.7453
RCH-ACV	CTRP2	-4.853	-2.0848	-4.8534	72.2867
MOLM-13	GDSC2; CTRP2	-4.7633	-1.7927	-4.7642	71.6118
Kasumi-2	CTRP2; CCLE	-4.7176	-2.7074	-4.7176	71.6398
BALL-1	GDSC2	-4.6212	-3.4566	-4.6212	62.2755
A3/Kawakami	GDSC2	-4.5935	-3.1419	-4.5937	61.981
Ci-1	CTRP2; CCLE	-4.5317	-0.6967	-4.5398	69.6042
ATN-1	GDSC2	-4.5144	-3.2425	-4.5144	61.2006
Mino	CTRP2; CCLE	-4.5095	-3.679	-4.5095	70.3117
JVM-2	GDSC2; CTRP2	-4.4997	-0.5763	-4.5094	69.3411
697	GDSC2; CTRP2; CCLE	-4.4846	-3.9206	-4.4846	70.1454
L-540	GDSC2; CTRP2	-4.3753	-2.4524	-4.3753	69.387
SET-2	CTRP2	-4.3253	-3.816	-4.3253	69.0841
DoHH2	GDSC2; CTRP2; CCLE	-4.2632	-0.9095	-4.2668	68.2263
KMS-28BM	CTRP2	-4.2483	2.7562	-4.4914	65.0401
Hs 611.T	CTRP2	-4.2343	1.3307	-4.3204	66.3445
OCI-AML-3	GDSC2; CTRP2	-4.2163	-3.5792	-4.2163	68.3586
KOPN-8	GDSC2	-4.2061	-3.1153	-4.2061	58.1132
KE-37	GDSC2; CTRP2	-4.198	-2.876	-4.198	68.235
SCC-3	GDSC2	-4.1823	-3.474	-4.1823	57.8749
OCI-AML-5	GDSC2; CTRP2; CCLE	-4.0965	-1.4861	-4.097	67.4315
KHM-1B	CTRP2; CCLE	-4.0943	-1.0301	-4.0963	67.2737
CTV-1	GDSC2	-4.0718	-3.1102	-4.0718	56.7657
MC116	CTRP2; CCLE	-4.0426	-1.5272	-4.0429	67.0992
CCRF-CEM	GDSC2	-4.0376	-2.9154	-4.0376	56.4219
CMK-86	CCLE	-4.0325	-2.446	-4.0326	60.3865
Granta-519	GDSC2; CTRP2; CCLE	-4.0254	-1.9696	-4.0254	67.0549
DB	GDSC2; CTRP2	-4.0083	-0.7088	-4.0121	66.6233
HuNS1	CTRP2	-3.9083	-1.0507	-3.9095	66.1347
SUP-HD1	GDSC2; CTRP2	-3.8491	-0.3085	-3.862	63.0541
EM-2	GDSC2; CTRP2; CCLE	-3.8015	-1.822	-3.8015	65.5752
PF-382	GDSC2; CTRP2	-3.7955	-0.9615	-3.7968	65.4046
LC4-1	GDSC2	-3.7908	-1.0063	-3.8268	53.7926
KMS-27	CTRP2	-3.7801	-1.3086	-3.7804	65.3791
Mono-Mac-1	CTRP2; CCLE	-3.7652	-1.2689	-3.7656	65.2768
WSU-NHL	GDSC2	-3.7499	-1.9297	-3.7526	53.5184
KO52	CTRP2; CCLE	-3.7301	-2.3697	-3.7301	65.1182
NB4	CTRP2	-3.7141	-2.4837	-3.7141	65.0123
EB1	CTRP2; CCLE	-3.7122	1.5812	-3.7947	63.5592
VL51	GDSC2	-3.6848	0.3413	-3.8805	52.5251
BDCM	CTRP2; CCLE	-3.6841	-1.2385	-3.6844	64.7496
SUP-M2	GDSC2; CCLE	-3.683	-2.4004	-3.683	57.3944
SU-DHL-4	CTRP2; CCLE	-3.6736	-1.3678	-3.6738	64.6985
RPMI-6666	GDSC2; CTRP2	-3.6421	-1.4977	-3.6422	64.5056
HuT 78	CTRP2; CCLE	-3.6208	-0.8586	-3.622	64.2766
MEC-1	CCLE	-3.6018	-0.3092	-3.638	56.4166
EHEB	CTRP2	-3.5915	2.616	-3.7721	62.1892
Reh	GDSC2; CTRP2; CCLE	-3.5871	-1.7771	-3.5871	64.1584
MOLP-2	CTRP2	-3.5659	-0.5356	-3.5685	63.8527
SUP-B15	GDSC2; CTRP2	-3.4977	-2.2555	-3.4977	63.5704
BL-41	GDSC2; CCLE	-3.4967	-2.1326	-3.4967	55.7939
BC-1	GDSC2	-3.4445	-0.2217	-3.5366	50.4405
H9	GDSC2	-3.4127	-1.7309	-3.4149	50.1517
TK [Human B-cell lymphoma]	GDSC2	-3.3899	-0.4021	-3.4582	49.9271
Namalwa	GDSC2; CTRP2	-3.3635	0.0898	-3.3714	62.411
SIG-M5	CTRP2; CCLE	-3.3601	-1.2713	-3.3602	62.6373
MOTN-1	CTRP2	-3.3525	2.6056	-3.517	61.013
NALM-6	GDSC2; CTRP2	-3.3344	-1.6933	-3.3344	62.4802
SK-MM-2	GDSC2; CTRP2; CCLE	-3.3237	1.5341	-3.3867	61.5176
MLMA	GDSC2	-3.3113	2.3286	-3.9786	49.3517
IM-9	GDSC2	-3.3049	-1.0418	-3.3227	49.0853
HC-1	GDSC2	-3.3025	-1.6432	-3.3048	49.0483
SKM-1	GDSC2; CTRP2	-3.2758	-2.1068	-3.2758	62.0925
SUP-T11	CTRP2	-3.262	3.0866	-3.4839	60.2504
BL-70	CTRP2; CCLE	-3.216	0.4316	-3.2285	61.395
VAL	GDSC2	-3.2145	-0.8649	-3.2382	48.1974
EoL-1	GDSC2	-3.1892	-1.3353	-3.1951	47.9208
GA-10	GDSC2; CTRP2	-3.1648	0.9217	-3.191	60.9047
ML-2	GDSC2	-3.1604	-1.3461	-3.1657	47.6321
P31/FUJ	CTRP2; CCLE	-3.1284	-0.535	-3.1294	61.058
KMS-20	CTRP2	-3.1258	-0.4136	-3.1273	61.0259
KMS-26	CTRP2; CCLE	-3.089	-0.9242	-3.0892	60.8321
RL	CTRP2	-3.047	2.7178	-3.2062	59.3647
SU-DHL-6	GDSC2; CTRP2; CCLE	-3.0184	-1.1244	-3.0184	60.372
KMS-21-BM	CTRP2	-2.9762	0.0329	-2.98	59.9948
MOLM-6	CTRP2	-2.9661	0.2065	-2.9717	59.8981
HPB-ALL	CTRP2	-2.924	1.2025	-2.9554	59.3621
CESS	GDSC2	-2.8841	0.1047	-2.9823	45.111
OCI-M1	GDSC2; CTRP2	-2.8756	-1.6246	-2.8756	59.4263
WSU-DLCL2	CTRP2	-2.857	-1.4241	-2.857	59.302
ARH-77	GDSC2	-2.8453	-1.0783	-2.8518	44.4826
WIL2 NS	GDSC2	-2.8285	-1.738	-2.8287	44.2906
ALL-PO	GDSC2	-2.7956	0.8475	-3.0164	44.54
P30/OHK	GDSC2	-2.7117	-1.1088	-2.7157	43.1344
EB2	GDSC2; CCLE	-2.6768	-1.3978	-2.6769	48.7541
Daudi	GDSC2; CTRP2	-2.644	-0.0977	-2.6453	57.855
Pfeiffer	CTRP2; CCLE	-2.6406	1.5353	-2.6796	57.5452
GDM-1	GDSC2; CTRP2	-2.6216	3.1383	-2.8072	56.8757
Karpas-422	GDSC2; CTRP2; CCLE	-2.6172	0.9923	-2.6479	54.5525
JM-1	CCLE	-2.5853	-0.7894	-2.587	47.9708
HAL-01	GDSC2	-2.5152	-1.1964	-2.5165	41.1517
OCI-AML-2	GDSC2; CTRP2; CCLE	-2.5001	-0.7129	-2.5001	56.9228
JURL-MK1	GDSC2; CTRP2	-2.4836	-0.6345	-2.4837	56.8126
THP-1	CTRP2	-2.4227	1.4851	-2.4529	56.2147
SR	GDSC2; CTRP2	-2.3165	-1.4768	-2.3165	55.7017
KMS-12-BM	GDSC2; CTRP2; CCLE	-2.3102	0.2976	-2.3123	55.6376
Ki-JK	CTRP2	-2.3043	1.7612	-2.3445	55.4227
Jurkat	GDSC2; CTRP2; CCLE	-2.2903	-0.2906	-2.2905	55.5237
Peer	CTRP2	-2.2429	3.3067	-2.426	54.6964
NCO2	CTRP2; CCLE	-2.1951	0.3255	-2.1969	54.8779
TF-1	CTRP2	-2.1683	0.3622	-2.1702	54.6995
MM1.S	GDSC2; CTRP2	-2.0762	-0.4684	-2.0762	54.1004
MOLP-8	GDSC2; CTRP2; CCLE	-2.0698	2.1385	-2.1244	53.8972
RPMI-8866	GDSC2	-2.0563	1.3454	-2.3261	37.6942
A4/Fukuda	GDSC2; CTRP2	-2.0036	0.4637	-2.0053	53.6075
HL-60	GDSC2; CTRP2	-1.9956	-0.4969	-1.9956	53.5634
PL21	CTRP2	-1.9929	0.4377	-1.9944	53.5372
U-937	CTRP2; CCLE	-1.9563	-0.6159	-1.9563	53.302
NOMO-1	GDSC2; CTRP2	-1.9519	-0.2009	-1.952	53.272
M-07e	CTRP2	-1.9351	1.2502	-1.9469	53.1245
L-363	GDSC2; CTRP2; CCLE	-1.9147	0.421	-1.9159	53.0194
AMO1	GDSC2; CTRP2; CCLE	-1.9078	0.8697	-1.9124	52.9624
Karpas-1106P	GDSC2	-1.8301	1.7827	-2.1978	35.9137
SU-DHL-10	GDSC2; CTRP2; CCLE	-1.8244	0.4611	-1.8255	52.4195
HEL	GDSC2; CTRP2	-1.8218	-0.9136	-1.8218	52.4058
KG-1	GDSC2; CCLE	-1.7724	1.935	-1.9609	41.5738
NCI-H929	GDSC2; CTRP2	-1.7374	0.6518	-1.7391	51.8397
BE-13	GDSC2	-1.721	2.8631	-2.4379	36.2368
Raji	GDSC2; CTRP2; CCLE	-1.6451	1.0032	-1.6492	51.2239
OCI-Ly10	CTRP2; CCLE	-1.6236	3.7003	-1.8201	50.9914
ST486	GDSC2; CTRP2	-1.5992	2.2342	-1.6423	50.8979
GR-ST	GDSC2	-1.5844	7.1451	-4.1359	40.0032
OPM-2	GDSC2; CTRP2; CCLE	-1.4363	2.3572	-1.4811	49.842
Jiyoye	GDSC2	-1.4236	1.7526	-1.7456	31.779
HT	CTRP2; CCLE	-1.3385	2.7354	-1.4064	49.2138
KMOE-2	GDSC2	-1.3022	1.7172	-1.6029	30.4845
Farage	GDSC2	-1.2698	3.1048	-2.046	32.3653
TUR	GDSC2	-1.1895	0.1039	-1.2	27.8949
EJM	GDSC2; CTRP2	-1.1776	2.7765	-1.2415	48.1715
LAMA-84	GDSC2; CTRP2	-1.1444	0.5182	-1.1445	47.8929
MJ	CTRP2; CCLE	-1.1354	1.3475	-1.1393	47.8386
CA46	GDSC2; CTRP2	-1.1035	3.5319	-1.2414	47.753
KM-H2	GDSC2; CTRP2	-1.0858	0.8782	-1.0865	47.5038
Ku812	GDSC2; CTRP2; CCLE	-1.0796	1.428	-1.084	47.4684
RC-K8	GDSC2	-0.9911	2.6694	-1.5824	28.8831
L-428	GDSC2; CTRP2; CCLE	-0.9828	1.2118	-0.9845	46.8196
U-698-M	GDSC2	-0.8855	2.2243	-1.3093	27.0056
MEG-01	GDSC2; CCLE	-0.8646	2.0669	-1.0043	33.772
Karpas-299	GDSC2; CTRP2; CCLE	-0.7874	1.2293	-0.7885	45.5172
HEL 92.1.7	CTRP2; CCLE	-0.6092	-0.3135	-0.6092	44.327
JJN-3	GDSC2; CTRP2	-0.5767	4.918	-0.9079	44.6785
ME1	CTRP2	-0.5729	4.0527	-0.7472	44.4201
DG-75	GDSC2	-0.5648	2.5355	-1.0752	24.3086
KCL-22	GDSC2; CTRP2; CCLE	-0.5585	2.2622	-0.5734	44.0272
MN-60	GDSC2	-0.4592	3.5799	-1.3885	25.5128
HH [Human lymphoma]	GDSC2; CTRP2; CCLE	-0.4521	4.5524	-0.7009	43.7751
CMK	CTRP2	-0.4475	-0.0586	-0.4475	43.25
MOLT-4	GDSC2	-0.4329	2.9683	-1.1044	23.8904
Kasumi-1	GDSC2; CTRP2	-0.1939	3.1988	-0.2473	41.7049
Ramos.2G6.4C10	GDSC2	-0.1665	1.3779	-0.2742	18.1369
MHH-PREB-1	GDSC2	-0.1291	2.8517	-0.737	20.5589
RPMI-8226	GDSC2; CTRP2	0.0372	2.127	0.0337	40.032
HDLM-2	GDSC2; CTRP2	0.1663	3.1593	0.1304	39.2702
Loucy	GDSC2	0.1907	2.0902	-0.0994	15.5681
U266B1	GDSC2; CTRP2	0.2157	6.6699	-0.4979	40.5117
KMS-18	CTRP2	0.3298	5.5521	-0.0649	39.1268
K-562	GDSC2; CTRP2	0.3462	3.3829	0.3021	38.0994
KMS-11	CTRP2; CCLE	0.5213	3.3246	0.4881	36.902
ME1	GDSC2	0.5309	4.7782	-0.9571	19.2544
F-36P	CTRP2; CCLE	0.69	3.7062	0.6356	35.8468
LP-1	GDSC2; CTRP2; CCLE	1.3087	3.0994	1.2922	26.7236
Mono-Mac-6	CTRP2	2.201	14.3714	-1.6363	35.9445
Karpas-45	GDSC2	2.5996	5.3739	0.4547	4.6859
MHH-CALL-3	CTRP2	3.0666	16.8859	-2.0216	34.3566
L-1236	GDSC2; CTRP2	3.2099	8.0763	2.2305	22.4439
P3HR-1	CTRP2; CCLE	4.6833	15.3974	0.1902	25.4474
Toledo	CTRP2; CCLE	7.7819	26.5314	-2.7896	26.4385
Karpas-620	GDSC2; CTRP2; CCLE	7.8482	9.2939	5.5674	0.2739
REC-1	CTRP2	8.2151	15.7233	2.8728	9.5298
KMM-1	CTRP2; CCLE	8.9478	23.6734	-0.483	19.3351

Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE8	CTRP2	-0.9337	6.491	-1.6975	47.1783
TE15	CTRP2	-0.3335	1.0921	-0.3336	42.4907
TE-15	GDSC2; CCLE	-3.353	-0.5843	-3.3692	54.4695
TE-11	CTRP2; CCLE	-2.3425	0.753	-2.3498	55.8144
TE-4	GDSC2; CTRP2	-2.221	2.7327	-2.3334	54.7087
KYSE-510	GDSC2; CTRP2; CCLE	-2.104	-0.3961	-2.104	54.285
TE-5	GDSC2; CTRP2; CCLE	-1.7388	1.6732	-1.7593	51.8233
EC-GI-10	GDSC2; CTRP2	-1.1815	5.3796	-1.6704	48.4192
KYSE-270	GDSC2	-1.0178	2.4029	-1.5145	28.6718
OE33	GDSC2; CTRP2; CCLE	-0.7248	3.012	-0.7872	45.2184
OE21	GDSC2; CTRP2; CCLE	-0.6772	2.6229	-0.711	44.8533
TE-14	CTRP2	-0.2823	2.7543	-0.3105	42.2266
TE-9	GDSC2; CTRP2; CCLE	0.3717	2.729	0.3609	37.8273
TE-1	GDSC2; CTRP2; CCLE	0.5366	4.3575	0.396	37.1224
KYSE-410	GDSC2; CTRP2; CCLE	0.6971	2.0323	0.697	35.6248
TE-10	CTRP2	0.7313	3.943	0.6561	35.6375
TE-8	GDSC2	0.7399	5.3786	-1.0552	19.0669
TE-6	GDSC2; CTRP2	1.0842	4.5503	0.9537	33.4713
KYSE-180	GDSC2; CTRP2; CCLE	1.2894	2.8997	1.2872	31.6858
KYSE-520	GDSC2; CTRP2; CCLE	2.2236	4.405	2.1822	25.594
COLO 680N	GDSC2; CTRP2	2.2281	7.2961	1.4813	27.9935
KYSE-30	CTRP2; CCLE	2.3581	8.1354	1.3057	28.1782
KYSE-450	GDSC2; CTRP2; CCLE	2.7041	9.2793	1.1964	27.5021
KYSE-150	CTRP2; CCLE	3.0974	9.0183	1.7155	24.6171
KYSE-70	GDSC2; CTRP2; CCLE	4.0159	9.5108	2.4256	19.5474
KYSE-140	GDSC2; CTRP2; CCLE	4.1735	9.4267	2.6208	18.3966
OE19	GDSC2; CTRP2	4.5786	8.124	3.6245	13.4042

Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	0.9309	5.2702	0.6546	34.9321
HuP-T4	GDSC2; CTRP2; CCLE	-2.498	2.4277	-2.5951	56.426
L3.3	CTRP2; CCLE	-2.2493	-1.2095	-2.2493	55.2539
MIA PaCa-2	GDSC2; CTRP2; CCLE	-1.6917	1.7821	-1.7152	51.5121
PaTu 8988s	CTRP2	-1.5791	5.8842	-2.2321	50.6325
Panc 03.27	CTRP2; CCLE	-1.5139	1.5047	-1.5251	50.3515
SW1990	CTRP2; CCLE	-1.0471	3.6528	-1.197	47.4053
Capan-1	GDSC2; CTRP2	-0.9815	3.3592	-1.0912	46.9488
KP-4	GDSC2; CTRP2; CCLE	-0.8552	2.4787	-0.887	46.0246
PL4	GDSC2	-0.7161	2.711	-1.3036	26.2009
PSN1	GDSC2; CTRP2; CCLE	-0.6262	3.1692	-0.6973	44.588
PL45	CCLE	-0.6177	1.601	-0.6724	31.3046
SU.86.86	GDSC2; CTRP2; CCLE	-0.449	2.0169	-0.4558	43.2789
Panc 02.03	GDSC2; CTRP2; CCLE	-0.3636	3.6929	-0.881	30.2777
BxPC-3	GDSC2; CTRP2; CCLE	-0.2753	3.5453	-0.3647	42.3264
CFPAC-1	GDSC2; CTRP2	-0.2623	3.5077	-0.3472	42.231
Panc 10.05	GDSC2; CTRP2; CCLE	0.0366	3.9401	-0.0802	40.3459
YAPC	GDSC2; CTRP2	0.1548	4.9037	-0.1115	39.9417
Panc 04.03	CTRP2; CCLE	0.1591	3.3865	0.1066	39.3657
Panc 08.13	GDSC2; CTRP2	0.2793	2.4528	0.2735	38.4264
PK-1	CCLE	0.2955	5.1921	-0.7439	27.8625
DAN-G	GDSC2; CTRP2	0.4686	2.7732	0.4583	37.1804
KCI-MOH1	CCLE	0.5776	9.8626	-2.6124	33.1496
SUIT-2	GDSC2; CTRP2; CCLE	0.697	7.1556	-0.1287	37.8499
KP-3	GDSC2; CTRP2; CCLE	0.7124	4.1318	0.6143	35.8339
KP-1NL	CCLE	0.9589	5.4639	-0.1756	22.9043
HuP-T3	GDSC2; CTRP2; CCLE	1.1584	3.6248	1.1298	32.6461
HPAF-II	GDSC2; CTRP2; CCLE	1.4276	4.3144	1.3516	31.0111
KP-1N	GDSC2; CCLE	1.4742	3.3515	1.2271	14.2416
Capan-2	GDSC2; CTRP2; CCLE	1.6627	3.7168	1.6456	29.2489
AsPC-1	GDSC2; CTRP2; CCLE	1.8778	5.9955	1.5105	29.0035
PK-59	CTRP2; CCLE	1.9265	4.6914	1.8346	27.7443
TCC-Pan2	CTRP2	2.144	6.7889	1.5634	27.9782
PaTu 8988t	GDSC2; CTRP2	2.2271	5.292	2.0572	26.0115
SNU-410	CTRP2	2.3263	11.7093	-0.2714	32.7668
Panc 05.04	CTRP2	2.5721	8.5611	1.3609	27.3504
PaTu 8902	GDSC2; CTRP2; CCLE	2.7486	9.0597	1.3366	26.9113
HPAC	GDSC2; CTRP2; CCLE	2.7914	6.3678	2.401	23.0425
SNU-213	CTRP2	2.8155	4.0963	2.811	21.5265
QGP-1	GDSC2; CTRP2; CCLE	3.2187	8.4693	2.0762	22.9845
Hs 766T	CTRP2; CCLE	3.2294	6.8758	2.7109	20.608
PK-45H	CTRP2; CCLE	3.9868	8.8595	2.6946	18.588
KP-2	GDSC2; CTRP2; CCLE	4.1608	10.1854	2.2517	19.8417

Cancer Drug Sensitivity Data Curated from 65 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	2.0873	10.9298	-0.6193	30.5746
WM266-4	CTRP2; CCLE	-3.2671	-2.3975	-3.2671	62.0344
Hs 944.T	CTRP2; CCLE	-2.4623	1.2176	-2.483	56.5146
RPMI-7951	GDSC2; CTRP2; CCLE	-2.0614	1.7415	-2.0931	53.8965
LOX-IMVI	GDSC2; CTRP2; CCLE	-1.999	1.8302	-2.0331	53.4892
G-mel	GDSC2	-1.7299	1.6471	-2.0498	34.7514
SK-MEL-24	GDSC2; CTRP2; CCLE	-1.628	3.3525	-1.7766	51.036
COLO 800	CTRP2	-1.3788	2.4335	-1.4262	49.4684
UACC-62	GDSC2; CTRP2; CCLE	-1.3316	2.9417	-1.4173	49.1752
CJM [Human melanoma]	CTRP2	-1.0541	1.6155	-1.0611	47.3025
WT2-iPS	GDSC2; CTRP2; CCLE	-1.0283	4.3951	-1.2945	47.3831
IGR-37	GDSC2; CTRP2; CCLE	-0.766	1.1492	-0.7667	45.3738
A-375	GDSC2; CTRP2; CCLE	-0.5484	2.9005	-0.5948	44.0291
IGR-39	CTRP2; CCLE	-0.503	2.0954	-0.5123	43.6447
COLO 679	GDSC2; CCLE	-0.4788	3.3092	-0.8853	31.5958
Hs 294T	CTRP2; CCLE	-0.4475	3.6545	-0.5594	43.4992
A2058	GDSC2; CTRP2; CCLE	-0.4402	3.5332	-0.5378	43.4232
WM88	CTRP2; CCLE	-0.2281	3.6502	-0.3264	42.0374
G-361	GDSC2; CTRP2; CCLE	-0.214	3.7145	-0.3188	41.9597
SK-MEL-5	GDSC2; CTRP2; CCLE	-0.1575	2.3162	-0.1665	41.3449
M14	GDSC2	-0.1184	4.6962	-1.5469	24.9078
CHL-1	GDSC2; CCLE	-0.1101	4.2294	-0.7944	29.678
COLO 829	GDSC2; CTRP2	0.0151	4.7338	-0.2297	40.7898
WM793	GDSC2; CTRP2; CCLE	0.0896	4.1675	-0.0547	40.068
Mel Ho	CTRP2; CCLE	0.2705	3.397	0.2222	38.6143
Hs 695T	CCLE	0.2738	4.2197	-0.3789	26.3619
HT-144	GDSC2; CTRP2; CCLE	0.2752	2.9848	0.2525	38.5067
WM35	GDSC2	0.4035	6.0135	-1.6773	23.5588
WM983B	CTRP2; CCLE	0.4891	3.2884	0.457	37.1126
WM278	GDSC2	0.5824	6.3402	-1.6724	22.8899
HMV-II	GDSC2	0.6286	9.5259	-3.2082	29.0768
K029AX	CTRP2; CCLE	0.722	4.497	0.5735	35.9233
A101D	GDSC2; CTRP2	0.8022	4.6616	0.633	35.4565
WM1552C	GDSC2	0.8469	4.9644	-0.7534	16.9642
WM1799	CTRP2; CCLE	0.9175	6.0102	0.4585	35.5449
SK-MEL-1	CTRP2	0.9262	7.0515	0.1546	36.319
RVH-421	CTRP2; CCLE	1.109	2.6611	1.1077	32.8846
SH-4	GDSC2	1.3223	3.6856	0.3084	8.8788
UACC-257	GDSC2; CTRP2; CCLE	1.4002	6.2427	0.9206	32.4921
SK-MEL-3	CTRP2	1.404	4.0249	1.3562	31.0746
HMCB	CTRP2; CCLE	1.4865	4.3742	1.407	30.6312
GAK	GDSC2	1.6469	3.2138	0.8215	4.6566
Hs 852.T	CTRP2; CCLE	1.6861	7.0121	0.9925	31.3124
COLO 741	CTRP2; CCLE	1.7046	6.8495	1.0662	31.0205
IGR-1	GDSC2; CTRP2	1.7609	7.2822	0.9815	31.1014
MDA-MB-435S	CTRP2; CCLE	1.7715	5.5147	1.5145	29.334
WM115	GDSC2; CTRP2; CCLE	1.7715	5.0866	1.6035	29.0335
Malme-3M	CCLE	1.9192	7.0028	0.0393	18.7453
CP66-MEL	GDSC2	1.976	5.1934	0.0954	8.3417
IPC-298	CTRP2; CCLE	2.1098	7.3567	1.332	28.8605
Hs 938.T	CCLE	2.4066	8.7067	-0.3618	19.232
Mel JuSo	GDSC2; CTRP2	2.6528	4.9832	2.5695	22.8778
MeWo	CTRP2; CCLE	2.7138	7.5831	1.8981	25.0791
SK-MEL-2	GDSC2; CCLE	2.775	3.8498	2.3756	3.9883
SK-MEL-31	CTRP2; CCLE	2.9454	7.2876	2.2568	23.1071
COLO 792	GDSC2; CTRP2	3.3932	6.548	2.9994	19.0623
Hs 895.T	CTRP2; CCLE	3.5413	12.5503	0.5263	27.2619
SK-MEL-30	CTRP2; CCLE	3.7105	9.2747	2.228	21.0871
SF8657	CCLE	3.8216	13.4149	-1.5396	20.5305
Hs 936.T	CTRP2; CCLE	5.2484	12.3467	2.2075	17.4704
Hs 940.T	CTRP2	5.7957	9.6968	4.007	9.0532
Hs 688(A).T	CTRP2	6.3231	14.8184	1.8874	16.4537
SK-MEL-28	CTRP2	6.5378	8.9108	4.9987	3.53
Hs 934.T	CTRP2	6.6564	13.7414	2.6933	12.78
Hs 839.T	CTRP2	6.7586	9.9519	4.6492	4.6213

Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ESO-26	GDSC2	-2.8285	-0.0044	-2.9088	44.5282
OACM5.1 C	GDSC2	-2.0516	1.7167	-2.4205	38.019
KYSE-220	GDSC2	-1.1686	2.2249	-1.6164	29.8968
TE-12	GDSC2	0.3041	7.1154	-2.3088	26.8147
FLO-1	GDSC2	0.842	7.2184	-1.8726	22.9624
ESO-51	GDSC2	0.9496	2.2531	0.6399	8.1302
OACP4 C	GDSC2	1.7379	5.2179	-0.1057	10.241
KYAE-1	GDSC2	2.1972	4.3226	0.6867	4.1341
KYSE-50	GDSC2	2.9149	9.157	-1.158	13.3316
SK-GT-4	GDSC2	3.0916	10.918	-1.8932	16.6105

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC2; CTRP2	-0.677	8.9434	-2.2456	46.3775

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IMR-32	CTRP2; CCLE	-6.7809	-3.5646	-6.7813	83.4679
MHH-NB-11	CTRP2	-5.718	-4.1618	-5.718	78.3151
CHP-126	CTRP2	-5.4972	-1.6539	-5.502	75.4049
IMR-5	GDSC2	-4.9086	-3.3754	-4.9087	65.1159
SiMa	GDSC2; CTRP2; CCLE	-4.3733	-2.5168	-4.3733	69.3799
SK-N-BE(2)	CTRP2; CCLE	-3.8677	5.8083	-4.7094	60.9567
NB69	GDSC2	-3.6469	-1.6012	-3.6536	52.4781
SJNB-14	GDSC2	-3.5733	1.8897	-4.1305	51.3446
NH-6	CTRP2	-3.5452	0.2207	-3.5579	63.4565
Kelly	GDSC2; CTRP2; CCLE	-3.1717	-0.4337	-3.1732	61.3251
SJNB-10	GDSC2	-2.8406	0.1393	-2.9406	44.695
SK-N-SH	CTRP2; CCLE	-2.5292	3.875	-2.8217	56.0928
NH-12	GDSC2	-2.1437	0.8551	-2.3107	38.1398
NB1	CTRP2	-2.0018	-0.1603	-2.0019	53.6036
KP-N-SI9s	CTRP2; CCLE	-1.9342	2.6216	-2.0208	52.9888
CHP-212	GDSC2; CTRP2; CCLE	-1.6701	4.5428	-2.0174	51.2118
SK-N-DZ	GDSC2; CTRP2; CCLE	-1.6177	5.7746	-2.2453	50.8428
SK-N-AS	GDSC2; CTRP2; CCLE	-1.3639	3.4256	-1.505	49.3953
SJNB-13	GDSC2	-0.9897	4.6597	-2.4061	32.4934
NB(TU)1	GDSC2	-0.8804	4.9616	-2.4303	32.0907
CHP-134	GDSC2	-0.7337	4.0812	-1.8891	29.1597
GOTO	GDSC2	0.053	8.3396	-3.1408	30.8516
TGW	GDSC2	0.064	5.8496	-1.9176	25.9853
SJNB-7	GDSC2	0.644	2.5225	0.208	11.9058
SK-N-BE(2)-M17	GDSC2	1.1173	5.5384	-0.7939	16.2995
SK-N-FI	CTRP2; CCLE	2.1488	5.5986	1.9059	26.7845
GI-ME-N	GDSC2	3.2729	9.4639	-1.0519	11.9309
KP-N-YN	GDSC2; CTRP2	9.0119	24.6907	-0.936	20.406

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-478	CTRP2	-1.9097	1.5192	-1.9287	52.9422
SNU-869	CTRP2	-0.1811	5.1194	-0.5213	42.2323
SNU-1196	CTRP2	0.0232	3.7916	-0.0763	40.3901
HuCC-T1	GDSC2; CTRP2; CCLE	0.662	6.0474	0.1696	37.2628
SNU-1079	CTRP2	1.2895	7.4078	0.428	34.3077
HuH-28	CTRP2	2.3234	8.1094	1.2789	28.3722
SNU-308	CTRP2	2.3651	4.3704	2.3332	24.6192

Cancer Drug Sensitivity Data Curated from 88 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-BR-3	CTRP2; CCLE	-5.1487	1.1305	-5.2603	70.5002
CAL-148	CTRP2	-4.4297	0.0972	-4.4551	68.4247
DU4475	GDSC2; CTRP2	-3.993	1.7822	-4.106	64.7917
MDA-MB-157	GDSC2; CTRP2; CCLE	-3.2524	3.2676	-3.5004	60.0892
MDA-MB-468	GDSC2; CTRP2; CCLE	-2.3804	0.5514	-2.3852	56.0793
MDA-MB-453	GDSC2; CTRP2; CCLE	-1.8761	1.5731	-1.8962	52.7209
HCC2157	GDSC2	-1.1717	0.7795	-1.248	28.0519
AU565	GDSC2; CTRP2; CCLE	-1.0247	2.6817	-1.075	47.163
CAL-51	GDSC2; CTRP2	-0.9686	3.3729	-1.0791	46.8667
HCC38	GDSC2; CTRP2	-0.825	4.6727	-1.1274	46.1706
BT-549	GDSC2; CTRP2; CCLE	-0.7768	4.2337	-0.9951	45.7751
HCC1806	GDSC2; CTRP2; CCLE	-0.7459	1.9821	-0.7563	45.2619
HCC2218	CTRP2	-0.1512	4.9562	-0.454	41.9721
CAL-85-1	GDSC2; CTRP2; CCLE	-0.1196	4.4103	-0.3172	41.5526
HCC70	GDSC2; CCLE	-0.1166	6.4433	-1.7081	33.0669
OCUB-M	GDSC2	0.4235	2.4528	0.0076	13.9743
HCC1500	GDSC2; CTRP2	0.6692	3.8434	0.6009	36.0281
MDA-MB-175-VII	CCLE	0.7188	4.1489	0.1239	22.3544
Evsa-T	GDSC2	0.7986	1.7771	0.6676	8.5965
ZR-75-1	CTRP2; CCLE	0.9474	7.4064	0.0583	36.4811
HCC1954	GDSC2; CTRP2; CCLE	1.0258	3.426	1.0039	33.5073
HCC1569	GDSC2; CTRP2; CCLE	1.1021	5.0246	0.891	33.6081
MDA-MB-436	GDSC2; CCLE	1.1064	6.9175	-0.6968	24.7385
HCC1395	CTRP2; CCLE	1.1107	7.8258	0.0867	35.8248
BT-20	GDSC2; CTRP2; CCLE	1.1251	4.1735	1.0473	33.0295
EFM-19	GDSC2; CCLE	1.132	5.7197	-0.1155	22.0227
HMC-1-8	CTRP2; CCLE	1.2395	5.8712	0.847	33.2686
HCC1143	GDSC2; CTRP2	1.4903	4.391	1.409	30.6117
HCC1419	GDSC2; CTRP2	1.7163	3.3399	1.7121	28.8487
UACC-812	CCLE	1.8105	8.4296	-0.7603	22.7492
Hs 739.T	CCLE	1.834	9.6014	-1.3165	24.9342
MDA-MB-415	GDSC2; CCLE	2.0623	6.8041	0.2694	17.1777
HCC1428	GDSC2; CTRP2	2.1958	6.3631	1.7532	27.1649
MRK-nu-1	GDSC2	2.2002	6.811	-0.5347	11.5994
MDA-MB-330	GDSC2	2.2767	6.7518	-0.447	10.8803
T-47D	GDSC2; CTRP2; CCLE	2.4009	13.6326	-1.0924	34.3611
COLO 824	GDSC2	2.4748	7.1962	-0.518	10.8035
MFM-223	GDSC2	2.6347	6.6219	-0.1214	8.0648
Hs 578T	GDSC2; CTRP2; CCLE	2.8095	5.6754	2.6075	22.2492
HCC1187	GDSC2; CCLE	2.88	9.7383	-0.4696	18.4412
MDA-MB-361	GDSC2; CTRP2	3.2283	10.3063	1.2739	25.7622
MCF-7	GDSC2; CTRP2; CCLE	3.7007	10.799	1.5132	23.6889
HDQ-P1	GDSC2; CTRP2; CCLE	3.8193	9.8963	2.052	21.4556
MDA-MB-231	GDSC2; CTRP2	4.1	10.4103	2.0861	20.614
EFM-192A	GDSC2	4.1232	6.2097	0.8945	0.6362
HCC1937	GDSC2; CTRP2	4.1936	11.6119	1.5998	22.1388
CAL-120	GDSC2; CTRP2	4.2073	7.8447	3.369	15.3772
JIMT-1	GDSC2; CTRP2	4.7837	7.2622	4.216	10.5253
HCC202	CTRP2	4.869	9.9879	3.0241	15.1215
ZR-75-30	GDSC2; CTRP2; CCLE	4.9429	7.0978	2.2548	1.059
Hs 578Bst	CTRP2	6.0482	11.1709	3.4844	10.7285
CAMA-1	GDSC2; CTRP2; CCLE	6.3793	15.9448	1.3704	18.1675
BT-474	GDSC2; CTRP2; CCLE	6.79	11.0509	4.1321	6.7047
KPL-1	CTRP2	10.6215	28.3515	-1.5631	19.6025
BT 416	CTRP2	-5.98	-4.8707	-5.98	80.0995
BT164	CTRP2	-5.3173	-2.5475	-5.3176	75.2418
BT 428	CTRP2	-4.8432	-2.2121	-4.8435	72.2845
BT 145	CTRP2	-4.3328	-2.1244	-4.3329	69.0684
BT 112	CTRP2	-3.571	2.6933	-3.7601	62.033
BT 245	CTRP2	-2.1012	8.6937	-3.6874	52.743
BT 271	CTRP2	-1.3804	6.3481	-2.1434	49.5783
BT 239	CTRP2	-1.0039	4.1739	-1.2295	47.2001
BT 504	CTRP2	-0.8959	6.7094	-1.7213	47.0119
BT 330	CTRP2	-0.78	6.3517	-1.4894	46.2868
BT 286	CTRP2	-0.5969	13.1875	-3.9032	46.9206
BT 131	CTRP2	-0.1535	9.8975	-2.0566	44.1411
BT 172	CTRP2	0.3822	8.0703	-0.7864	40.3802
BT 232	CTRP2	0.5147	12.1086	-2.2892	42.0121
BT 333	CTRP2	0.9644	12.5633	-2.0318	40.2327
BT147	CTRP2	1.3145	20.14	-5.2501	42.4381
BT 216	CTRP2	2.4146	13.0583	-0.809	33.7328
BT 228	CTRP2	2.5191	12.7208	-0.5482	32.8582
BT 482	CTRP2	2.6957	10.3627	0.7111	29.0398
BT 187	CTRP2	2.7362	11.8447	0.0745	30.7107
BT 139	CTRP2	2.7487	13.0672	-0.4862	32.0708
BT 440	CTRP2	3.8	12.2027	0.9407	25.3287
BT 231	CTRP2	4.126	14.5547	0.1011	27.0054
BT 340	CTRP2	4.3887	16.1327	-0.4383	27.8097
BT 328	CTRP2	5.621	9.9265	3.7401	10.5276
BT 224	CTRP2	5.6455	13.1063	2.1757	16.7441
BT 359	CTRP2	6.0391	13.2255	2.4494	14.9004
BT 159	CTRP2	6.7511	15.9305	1.6772	16.3982
BT 320	CTRP2	7.2	11.6161	4.153	5.9735
BT 248	CTRP2	7.4657	23.4238	-1.491	24.2436
BT 179	CTRP2	7.5257	12.7317	3.8403	6.751
BT 422	CTRP2	7.7034	16.8682	1.9452	13.7748
BT 444	CTRP2	7.93	16.2431	2.4184	11.6768
BT 498	CTRP2	8.0684	20.6986	0.3281	18.4644

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	1.1349	3.9295	1.0824	32.8816

Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SF539	GDSC2; CTRP2	-4.3506	-2.0406	-4.3507	69.167
SF268	GDSC2; CTRP2	-3.0738	2.5046	-3.21	59.6222
1321N1	CCLE	-2.8839	0.7468	-2.9752	50.5016
Daoy	GDSC2; CTRP2; CCLE	-2.6211	0.7232	-2.6313	57.6093
GB-1	GDSC2; CTRP2; CCLE	-2.3085	1.7862	-2.3502	55.4441
D283 Med	GDSC2; CTRP2	-2.2299	1.0205	-2.2409	55.0582
U-251MG	GDSC2; CTRP2	-2.1742	4.8551	-2.6303	53.9176
AM-38	GDSC2	-1.9752	0.4244	-2.056	36.108
8-MG-BA	GDSC2; CTRP2; CCLE	-1.8734	0.6965	-1.876	52.7401
KNS-60	CTRP2; CCLE	-1.8405	1.4476	-1.8558	52.4967
SNU-626	CTRP2	-1.5464	0.5748	-1.5472	50.5708
42-MG-BA	GDSC2; CTRP2; CCLE	-1.3394	2.8897	-1.4207	49.2237
H4	GDSC2; CCLE	-1.1917	1.6751	-1.2927	36.4042
SF126	CTRP2; CCLE	-1.0662	3.3524	-1.18	47.4952
SF295	CTRP2; CCLE	-0.9726	2.5923	-1.0149	46.812
Hs 683	CTRP2; CCLE	-0.5837	4.5562	-0.8438	44.6207
SK-MG-1	GDSC2	-0.4567	4.065	-1.5985	26.567
GI-1	GDSC2; CCLE	-0.3693	3.1007	-0.705	30.3822
M059J	GDSC2; CCLE	-0.2594	2.1225	-0.3617	28.438
Becker	GDSC2; CTRP2	-0.2338	5.9366	-0.9821	39.6467
U-118MG	GDSC2; CTRP2; CCLE	-0.033	4.337	-0.212	40.9506
ONS-76	GDSC2; CTRP2; CCLE	0.1943	4.3339	0.0326	39.4277
M059K	CTRP2	0.6911	5.027	0.4452	36.4106
D-263MG	GDSC2	0.7575	5.5672	-1.1318	19.4329
LN-18	GDSC2; CTRP2; CCLE	0.9156	3.3194	0.8957	34.2344
PFSK-1	GDSC2	0.9249	4.2229	-0.3176	14.0827
DK-MG	GDSC2; CTRP2; CCLE	1.1063	5.3603	0.8255	33.7966
GOS-3	CTRP2	1.3528	8.1265	0.236	34.6011
SNB-75	CTRP2	1.3927	7.5355	0.4946	33.7685
DBTRG-05MG	GDSC2; CTRP2; CCLE	1.508	8.3879	0.3023	33.8999
GMS-10	CTRP2; CCLE	1.5167	5.4531	1.2511	31.0474
KS-1 [Human Krukenberg tumour]	GDSC2	1.532	6.3169	-0.8253	15.1857
A-172	GDSC2; CTRP2; CCLE	1.6958	8.2251	0.5653	32.5524
KG-1-C	CTRP2	1.7336	5.0882	1.5622	29.2968
D-392MG	GDSC2	1.8399	6.435	-0.631	13.1491
GaMG	GDSC2; CTRP2; CCLE	2.0988	6.3232	1.6592	27.7936
LN-405	GDSC2	2.1738	5.6431	0.0233	8.2824
CAS-1	GDSC2; CTRP2; CCLE	2.1739	10.9776	-0.0939	32.7886
YH-13	GDSC2; CTRP2	2.2177	10.2027	0.294	31.6495
TM-31	CTRP2	2.4026	8.0042	1.4042	27.716
T98G	GDSC2; CTRP2; CCLE	2.5253	7.0373	1.8933	25.6608
NMC-G1	CTRP2	2.921	11.2522	0.5323	28.9229
MOG-G-CCM	CCLE	3.0923	7.2237	0.9645	10.7705
KINGS-1	GDSC2	3.1103	5.95	0.5045	3.4727
SNU-466	CTRP2	3.1708	4.9001	3.1309	19.2788
SW1088	GDSC2; CTRP2; CCLE	3.1859	9.6956	1.5075	25.0921
KNS-81	CTRP2; CCLE	3.6338	15.0364	-0.5904	29.9954
KALS-1	GDSC2; CTRP2; CCLE	3.7131	10.8996	1.4779	23.7782
U-87MG ATCC	GDSC2; CTRP2; CCLE	4.5171	12.6846	1.379	22.1219
LN-229	GDSC2; CTRP2; CCLE	4.6422	11.8502	1.9037	19.9723
YKG-1	CTRP2; CCLE	4.6456	10.183	2.7187	16.86
KNS-42	CTRP2; CCLE	5.4874	13.1394	2.0227	17.6486
CCF-STTG1	CTRP2	5.5056	10.2297	3.4874	11.8182
SW1783	CTRP2	6.1531	15.7233	1.2952	18.8657
SNU-201	CTRP2	7.0793	20.6609	-0.4203	22.2784
SNU-1105	CTRP2	8.9603	20.0428	1.3013	14.0154

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC2	1.4319	6.1073	-0.8051	15.3721
TGBC24TKB	GDSC2	2.8369	7.4899	-0.4005	9.2577

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ESS-1	GDSC2; CTRP2; CCLE	-5.4367	-2.8289	-5.4368	76.0948
JHUEM-2	CTRP2; CCLE	-4.4067	0.1977	-4.4351	68.2201
MFE-296	GDSC2; CTRP2; CCLE	-2.9052	1.4634	-2.9488	59.1556
JHUEM-7	CTRP2	-2.0456	3.4045	-2.2288	53.533
JHUEM-3	CTRP2	-2.0201	3.6318	-2.2347	53.3422
JHUEM-1	CTRP2	-1.0747	3.8322	-1.2518	47.6018
HEC-151	CTRP2; CCLE	-0.6865	1.2317	-0.6873	44.8447
HEC-50B	CTRP2	-0.0361	1.3351	-0.0362	40.5093
HEC-6	CTRP2; CCLE	0.1856	3.2136	0.1469	39.1499
MFE-280	GDSC2; CCLE	0.646	2.9856	0.4349	21.1667
RL95-2	GDSC2; CTRP2; CCLE	0.7332	4.2648	0.6193	35.7444
TEN	CCLE	1.604	3.9267	1.1517	14.1368
EFE-184	CTRP2; CCLE	1.7231	5.7003	1.4178	29.816
HEC-265	CTRP2; CCLE	1.8307	2.6817	1.8307	28.072
HEC-1-A	CTRP2; CCLE	1.9343	7.0936	1.2342	29.7373
KLE	GDSC2; CTRP2; CCLE	2.1233	8.8093	0.7872	30.5351
HEC-59	CTRP2; CCLE	2.2574	6.4161	1.8044	26.7952
HEC-108	CTRP2	2.3168	3.9384	2.3074	24.8651
HEC-251	CTRP2; CCLE	2.6168	6.8898	2.043	24.8533
HEC-1-B	CTRP2; CCLE	3.1164	7.6478	2.3029	22.4431
AN3-CA	GDSC2; CTRP2; CCLE	3.4072	9.1771	1.4939	19.5636
MFE-319	GDSC2; CTRP2; CCLE	3.4224	10.6475	1.31	25.1152
EN	GDSC2; CTRP2; CCLE	6.8544	11.9764	2.946	6.2782
Ishikawa (Heraklio) 02 ER-	CTRP2; CCLE	2.1733	3.5839	2.1702	25.8001

Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LB996-RCC	GDSC2	-4.1524	-0.8998	-4.2125	57.049
SW13	GDSC2	-2.4737	0.5353	-2.6083	41.2383
786-O	GDSC2; CTRP2; CCLE	-1.2191	1.432	-1.225	48.397
CAL-54	GDSC2; CTRP2	-1.0703	3.0952	-1.1572	47.4975
ACHN	GDSC2; CTRP2; CCLE	-1.0429	2.562	-1.1213	43.6388
KTCTL-195	GDSC2	-0.6316	6.7113	-2.9983	33.0303
UO-31	CTRP2	-0.5782	4.9821	-0.9232	44.707
BFTC-909	GDSC2; CTRP2; CCLE	-0.2673	3.7684	-0.3819	42.3303
SN12C	GDSC2	-0.2434	3.678	-1.2092	23.6547
Caki-1	CTRP2	0.4334	7.9765	-0.6974	40.0228
RXF 393L	GDSC2	0.4669	7.0172	-2.1112	25.369
HA7-RCC	GDSC2	0.5443	3.1088	-0.1546	14.4617
769-P	GDSC2; CTRP2; CCLE	0.592	3.4326	0.5544	36.4457
KMRC-20	GDSC2; CTRP2	1.0496	4.2287	0.9607	33.5675
KMRC-3	CTRP2	1.3193	7.6975	0.3576	34.3956
TK-10	GDSC2	1.4496	4.3606	0.0828	9.904
OS-RC-2	GDSC2; CTRP2	1.5955	5.6479	1.2914	30.6539
TUHR14TKB	CTRP2	1.6248	9.8347	-0.1612	34.6763
TUHR10TKB	CTRP2	1.8933	4.8563	1.7746	28.0565
VMRC-RCZ	GDSC2; CTRP2; CCLE	2.08	6.0879	1.706	27.6927
KMRC-1	CTRP2; CCLE	2.1243	7.8886	0.7993	25.891
A-704	GDSC2	2.3795	6.7404	-0.3643	10.1274
KMRC-2	CTRP2; CCLE	2.4391	6.3491	2.0225	25.4682
A-498	GDSC2; CTRP2	2.619	4.1972	2.6069	22.861
NCC010	GDSC2	3.2496	6.7821	0.2078	4.8907
TUHR4TKB	CTRP2	3.2965	8.5513	2.1223	22.5995
VMRC-RCW	CTRP2; CCLE	3.4578	6.5443	3.0707	18.6089
SNU-1272	CTRP2	4.0374	7.7529	3.2317	16.3665
RCC10RGB	GDSC2; CTRP2	4.5526	6.8024	4.1609	11.3672
Caki-2	CTRP2; CCLE	6.5051	12.5232	3.1805	11.1136

Cancer Drug Sensitivity Data Curated from 61 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW403	CCLE	-4.6974	1.097	-4.9679	62.7219
CL-34	CTRP2	-4.521	1.3745	-4.6236	67.612
SK-CO-1	GDSC2; CTRP2; CCLE	-2.8476	-0.3166	-2.8486	59.2052
SW48	GDSC2; CTRP2; CCLE	-2.3822	0.9478	-2.3938	56.0478
SW480	CCLE	-2.2006	0.6963	-2.2507	44.796
SNU-175	GDSC2; CTRP2	-1.3588	3.8398	-1.5573	49.3756
RCM-1 [Human ESC]	GDSC2; CTRP2	-0.8897	2.676	-0.9343	46.2711
GP2d	CTRP2	-0.8838	6.5392	-1.6572	46.9112
SNU-81	GDSC2; CTRP2	-0.6549	4.2096	-0.8599	44.9888
CaR-1	GDSC2	-0.6437	2.6294	-1.1952	25.3041
RKO	GDSC2; CTRP2; CCLE	-0.5444	2.5317	-0.5695	43.9565
SNU-C5	GDSC2; CTRP2	-0.5005	3.9973	-0.6614	43.9331
CCK-81	GDSC2; CTRP2; CCLE	-0.48	4.656	-0.7505	43.9863
LS513	GDSC2; CTRP2; CCLE	-0.3113	4.2202	-0.4924	42.7539
SW1417	GDSC2; CTRP2; CCLE	-0.2478	4.1111	-0.4075	42.2999
SNU-C2B	GDSC2; CCLE	-0.2371	3.8956	-0.8123	30.275
SW620	GDSC2; CTRP2; CCLE	-0.1962	4.2645	-0.3758	42.0083
HT-29	GDSC2; CTRP2; CCLE	-0.1591	1.8424	-0.1611	41.3346
SNU-C1	GDSC2; CTRP2	-0.1462	3.1881	-0.1967	41.3822
LoVo	GDSC2; CTRP2	-0.062	4.532	-0.2761	41.2175
CW-2	GDSC2; CTRP2	0.0988	4.6881	-0.1306	40.2153
CL-11	GDSC2; CTRP2	0.1347	5.6813	-0.3096	40.4653
NCI-H747	GDSC2; CTRP2; CCLE	0.1358	5.1163	-0.1762	40.1691
HCT 15	GDSC2; CTRP2; CCLE	0.1994	3.1576	0.1648	39.0465
T84	GDSC2; CTRP2; CCLE	0.2622	4.2216	0.1222	38.9257
LS180	GDSC2; CTRP2	0.2811	8.3832	-1.0094	41.1452
HT115	GDSC2; CTRP2	0.3165	4.6257	0.1158	38.7312
SNU-C2A	CTRP2; CCLE	0.3236	5.2324	0.0026	38.9896
LS1034	GDSC2; CTRP2	0.3425	4.4656	0.1708	38.4846
GP5d	GDSC2	0.3759	5.0332	-1.2274	21.3249
SW1463	GDSC2	0.3849	5.0629	-1.2331	21.3226
SW626	GDSC2	0.6766	4.1256	-0.5038	16.0774
MDST8	GDSC2; CTRP2	0.7095	4.6156	0.5409	36.0654
SNU-1033	CTRP2	0.7386	3.4947	0.7026	35.4652
HCC-56	CTRP2; CCLE	0.7426	3.9383	0.6686	35.5588
DiFi	GDSC2	0.7826	5.6505	-1.1499	19.4459
HCC2998	GDSC2	0.9201	7.5692	-1.9778	23.1943
NCI-H508	CTRP2	0.9889	3.9737	0.9247	33.8907
KM12	GDSC2; CTRP2	1.0999	3.3632	1.0831	32.9965
COLO 320	CTRP2; CCLE	1.306	6.4306	0.7628	33.2937
COLO 678	GDSC2; CTRP2; CCLE	1.3486	6.0707	0.9125	32.6929
COLO201	CTRP2; CCLE	1.4851	3.7895	1.4583	30.4643
SNU-407	GDSC2; CTRP2	1.5316	6.0377	1.1213	31.4183
SW948	GDSC2; CTRP2	1.5581	3.2887	1.5528	29.9062
C2BBe1	GDSC2; CTRP2; CCLE	1.588	5.4278	1.3345	30.5365
SW837	GDSC2	1.6409	4.577	0.1353	9.0094
DLD-1	CTRP2	1.7612	3.9474	1.7347	28.6242
SW1116	GDSC2; CTRP2	1.8631	7.3485	1.0687	30.4964
COLO205	GDSC2; CTRP2; CCLE	2.0696	7.2448	1.3282	28.9997
HCT 116	GDSC2; CTRP2; CCLE	2.1075	3.9044	2.0944	26.272
LS411N	GDSC2; CTRP2; CCLE	2.1351	7.2382	1.4013	28.5515
LS123	GDSC2; CTRP2; CCLE	2.1563	5.4813	1.9406	26.6406
SNU-C4	CTRP2	2.4292	4.1781	2.4124	24.141
SNU-1040	GDSC2	2.4985	4.8419	0.6403	3.7876
NCI-H716	GDSC2; CTRP2	2.6447	3.916	2.6414	22.6603
SNU-503	CTRP2	2.7837	8.1979	1.7317	25.4598
HT-55	GDSC2; CTRP2	2.892	7.3834	2.1639	23.6007
SNU-61	GDSC2; CTRP2	2.9171	7.0542	2.3108	22.9933
OUMS-23	CTRP2	3.3061	4.8829	3.2751	18.3473
COLO 320HSR	GDSC2	3.3811	5.5287	0.8326	1.449
HCT 8	CTRP2	4.036	5.9546	3.8765	13.9357

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC2	1.827	6.4936	-0.6706	13.4194

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHH-5	CTRP2; CCLE	-3.671	-1.6138	-3.671	64.7037
Li-7	CTRP2	-1.6384	1.8548	-1.6636	51.1631
HLF	CCLE	-1.5339	-0.2251	-1.5345	38.9407
HLE	GDSC2; CCLE	-0.9975	1.628	-1.0789	34.6699
HuH-1	GDSC2; CTRP2; CCLE	-0.6606	3.4145	-0.7578	44.8581
SNU-398	GDSC2; CTRP2; CCLE	-0.6161	5.7247	-1.1396	45.1596
JHH-4	GDSC2; CTRP2; CCLE	-0.3925	2.1485	-0.4013	42.908
SNU-182	CTRP2; CCLE	-0.1844	1.6722	-0.1855	41.5008
SNU-878	CTRP2	-0.0956	5.7613	-0.5812	41.9707
SNU-886	CTRP2	0.0517	2.5034	-0.0067	31.1414
JHH-7	GDSC2; CCLE	0.2235	4.6573	-0.6017	27.5355
SK-HEP-1	GDSC2; CTRP2; CCLE	0.5855	4.1025	0.3992	32.481
JHH-2	GDSC2; CTRP2; CCLE	0.866	8.1595	-0.2986	37.6018
Hep-G2	CTRP2; CCLE	0.869	6.6654	0.2152	36.3741
Hep-G2/C3A	GDSC2; CCLE	1.0292	6.7255	-0.6824	24.9396
SNU-475	CCLE	1.6152	8.9614	-1.201	25.1558
SNU-449	GDSC2; CTRP2; CCLE	2.2915	6.4417	1.8338	26.5868
SNU-423	GDSC2; CTRP2; CCLE	2.3224	7.5351	1.4962	27.6519
JHH-1	GDSC2; CTRP2	3.1184	5.3337	0.7816	1.8883
Huh-7	GDSC2	3.4408	5.1987	0.992	0.7528
JHH-6	GDSC2; CTRP2; CCLE	3.5797	5.1056	3.5409	16.5513
HuH-6	CTRP2	3.6194	5.5463	3.5154	16.5125
PLC/PRF/5	CTRP2; CCLE	3.7573	9.3914	2.2222	20.9857
SNU-387	GDSC2; CTRP2; CCLE	4.8672	13.6515	1.2202	21.8466
Hep 3B2.1-7	GDSC2; CTRP2; CCLE	5.0615	10.5338	2.9359	15.0366
SNU-761	CTRP2	5.6757	13.6858	1.9122	17.6601

Cancer Drug Sensitivity Data Curated from 199 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H1105	CTRP2	-8.0806	1.1817	-8.3663	78.3982
NCI-H146	CTRP2	-7.406	2.9132	-7.9134	74.4231
NCI-H209	GDSC2; CTRP2	-6.6806	6.0626	-7.8477	68.9438
NCI-H1876	GDSC2	-5.6021	-0.4139	-5.8171	66.8572
NCI-H2081	CTRP2	-4.9692	-0.6181	-4.9844	71.7788
NCI-H1048	GDSC2; CCLE	-4.5234	-1.9559	-4.5271	64.3374
NCI-H1694	GDSC2; CTRP2; CCLE	-4.299	-1.9389	-4.2991	68.8174
NCI-H1155	GDSC2; CTRP2; CCLE	-4.2701	-2.7691	-4.2701	68.7118
COR-L95	CTRP2	-3.9034	6.4409	-4.9227	60.645
Lu-99	CTRP2; CCLE	-3.6045	-0.0697	-3.6125	63.9332
NCI-H1734	CTRP2	-3.5819	-0.5505	-3.5844	63.9564
DMS 53	GDSC2; CTRP2	-3.3421	1.6826	-3.4164	61.5336
DMS 79	GDSC2; CTRP2	-3.3416	3.1049	-3.5718	60.6309
NCI-H526	GDSC2; CTRP2	-3.2559	-2.0534	-3.2559	61.9598
NCI-H1184	CTRP2; CCLE	-3.2433	1.0373	-3.2762	61.3158
COLO 668	GDSC2; CTRP2	-3.2193	-0.6197	-3.2202	61.6579
NCI-H211	GDSC2; CTRP2; CCLE	-3.108	0.19	-3.1147	60.7971
NCI-H2170	GDSC2; CTRP2; CCLE	-2.9984	0.7264	-3.0147	59.9692
EBC-1	GDSC2; CTRP2; CCLE	-2.9261	0.6857	-2.9401	59.535
HCC1438	CTRP2	-2.86	-0.8947	-2.8601	59.3165
NCI-H1781	GDSC2	-2.8388	0.3633	-2.9725	44.7562
DV-90	CTRP2; CCLE	-2.7595	1.548	-2.8029	58.2586
NCI-H2795	GDSC2	-2.7478	3.7892	-3.8863	45.5469
HCC78	GDSC2; CTRP2; CCLE	-2.7477	-1.1203	-2.7477	58.5733
NCI-H2122	GDSC2; CTRP2; CCLE	-2.6021	2.4407	-2.7058	57.0266
NCI-H1339	CTRP2; CCLE	-2.4926	0.3618	-2.4962	56.8277
LUDLU-1	CTRP2; CCLE	-2.4704	0.7021	-2.4783	56.6466
NCI-H2087	GDSC2; CTRP2; CCLE	-2.4309	0.556	-2.4363	56.408
SBC-5	GDSC2; CTRP2; CCLE	-2.3491	-1.302	-2.3491	55.9184
NCI-H2286	CTRP2; CCLE	-2.3144	2.0274	-2.3711	55.4311
NCI-H2228	GDSC2; CTRP2; CCLE	-2.0121	2.1536	-2.0655	53.5343
NCI-H82	GDSC2	-1.9533	2.9446	-2.7176	38.4505
NCI-H1568	GDSC2; CTRP2; CCLE	-1.8584	1.3036	-1.8702	52.6203
IST-SL2	GDSC2	-1.8517	0.1803	-1.8957	34.7028
COLO 677	CCLE	-1.7501	1.0734	-1.8123	41.0137
DMS 454	CTRP2	-1.6932	11.8665	-4.4802	50.8406
SK-MES-1	GDSC2; CTRP2; CCLE	-1.6251	2.6009	-1.6951	51.0519
RERF-LC-A1	CTRP2; CCLE	-1.6208	2.5288	-1.685	51.0274
HARA [Human squamous cell lung carcinoma]	GDSC2; CTRP2; CCLE	-1.5795	3.9913	-1.8185	50.7134
NCI-H1623	GDSC2; CTRP2	-1.5252	2.5062	-1.5836	50.4158
NCI-H446	GDSC2; CTRP2	-1.5171	4.6079	-1.8645	50.3279
NCI-H3122	GDSC2	-1.4487	1.1948	-1.6279	31.3376
NCI-H2810	GDSC2	-1.4401	2.5067	-2.0072	33.0516
NCI-H292	CTRP2	-1.4352	1.8127	-1.4538	49.8322
ABC-1	GDSC2	-1.4097	4.648	-2.8317	35.9728
Calu-3	GDSC2; CTRP2; CCLE	-1.3709	4.3302	-1.6528	49.4647
COR-L23	GDSC2; CCLE	-1.263	2.418	-1.5073	37.5243
NCI-H524	GDSC2; CTRP2	-1.2346	3.3365	-1.3567	48.5732
SW1271	GDSC2; CTRP2; CCLE	-1.2341	6.0279	-1.8944	48.7733
NCI-H1581	GDSC2; CTRP2; CCLE	-1.2078	2.9887	-1.2916	48.3801
PC-14	GDSC2; CTRP2; CCLE	-1.1773	2.7765	-1.2412	48.1696
NCI-H1693	GDSC2; CTRP2; CCLE	-1.1237	3.0417	-1.2083	47.8396
COR-L88	CTRP2	-1.0962	2.6742	-1.1489	47.6328
SBC-3	GDSC2	-1.0771	2.9527	-1.7817	30.2468
NCI-H2227	GDSC2	-1.0641	4.3844	-2.3612	32.6642
NCI-H2029	GDSC2; CTRP2	-1.0636	3.5699	-1.2038	47.502
EMC-BAC-2	GDSC2	-1.0015	3.3046	-1.8406	30.1623
Lu-99A	GDSC2	-0.9608	7.5744	-3.7275	36.4668
NCI-H1703	CTRP2; CCLE	-0.9306	3.215	-1.0219	46.5996
COR-L311	GDSC2	-0.8072	2.5437	-1.3385	26.7959
NCI-H1341	CTRP2; CCLE	-0.7948	1.8677	-0.8034	45.5829
LOU-NH91	GDSC2; CTRP2; CCLE	-0.7919	4.2409	-1.0125	45.8725
COR-L51	CTRP2	-0.74	5.7719	-1.2871	45.9113
SK-LU-1	GDSC2; CTRP2; CCLE	-0.6243	3.2335	-0.7013	44.5863
NCI-H1944	GDSC2; CTRP2; CCLE	-0.6088	3.3382	-0.6952	44.5021
NCI-H2110	CTRP2	-0.6075	2.6264	-0.6392	44.3885
Lu-135	GDSC2	-0.5378	4.5539	-1.9002	28.3531
NCI-H2171	CTRP2	-0.5243	1.3171	-0.5249	43.7635
LCLC-97TM1	GDSC2; CTRP2	-0.5023	2.023	-0.51	43.6356
NCI-H23	GDSC2; CTRP2; CCLE	-0.5007	3.994	-0.661	43.9331
NCI-H1385	CTRP2	-0.4824	4.4531	-0.7156	43.9406
NCI-H69	CTRP2	-0.4546	5.1575	-0.8272	43.9865
NCI-H2023	GDSC2; CTRP2; CCLE	-0.4537	1.2752	-0.4541	43.2925
NCI-H322	CTRP2; CCLE	-0.4495	3.0664	-0.5039	43.3941
NCI-H810	GDSC2; CTRP2; CCLE	-0.3104	4.8467	-0.6043	42.9595
NCI-H2141	GDSC2; CTRP2	-0.2263	6.2064	-0.844	42.9807
NCI-H2373	GDSC2	-0.2167	5.8819	-2.2024	28.3553
COR-L47	CTRP2	-0.1955	4.6548	-0.4425	42.1426
NCI-H2804	GDSC2	-0.1858	3.6876	-1.1545	23.1213
HOP-62	GDSC2; CTRP2	-0.1628	8.5274	-1.5394	43.6339
HCC15	GDSC2; CTRP2; CCLE	-0.1388	5.8274	-0.6455	42.272
SW1573	GDSC2; CTRP2; CCLE	-0.1107	6.4727	-0.7945	42.4005
NCI-H1651	GDSC2; CTRP2; CCLE	-0.0669	4.644	-0.3016	41.2941
NCI-H2030	CTRP2; CCLE	-0.052	5.7218	-0.5235	41.6768
DMS 114	GDSC2; CTRP2; CCLE	-0.0474	4.9379	-0.3376	41.2882
Lu-65	GDSC2; CTRP2	-0.0465	3.8876	-0.162	40.888
NCI-H1092	GDSC2; CTRP2; CCLE	-0.044	4.794	-0.3052	41.2046
DMS 273	GDSC2; CTRP2	-0.0065	4.8326	-0.2721	40.9742
NCI-H1666	GDSC2; CTRP2; CCLE	0.0023	4.3151	-0.1706	40.707
NCI-H1975	GDSC2; CTRP2; CCLE	0.0177	3.7662	-0.0793	40.4198
NCI-H322M	GDSC2	0.0317	5.7183	-1.8854	25.9605
NCI-H358	GDSC2; CTRP2; CCLE	0.0364	4.9737	-0.2541	40.7551
NCI-H522	GDSC2; CTRP2; CCLE	0.0387	4.8078	-0.2183	40.6656
COLO 699	CTRP2; CCLE	0.077	4.5266	-0.1253	40.2921
NCI-H520	GDSC2; CTRP2; CCLE	0.1031	4.8528	-0.1573	40.2599
NCI-H2461	GDSC2	0.1715	5.1043	-1.4571	23.3123
NCI-H1915	GDSC2; CTRP2; CCLE	0.195	5.8719	-0.293	40.1821
EPLC-272H	GDSC2; CTRP2	0.2096	4.777	-0.0274	39.5177
COR-L105	GDSC2; CTRP2; CCLE	0.2141	7.3721	-0.7249	40.9354
Calu-6	GDSC2; CTRP2; CCLE	0.2269	2.7797	0.2115	38.8058
KNS-62	GDSC2; CTRP2; CCLE	0.2819	4.4663	0.1055	38.8932
NCI-H460	CTRP2; CCLE	0.3056	3.1842	0.2732	38.3338
NCI-H1838	CTRP2	0.3177	2.542	0.3107	38.1746
RERF-LC-Sq1	GDSC2	0.3204	5.6312	-1.5691	23.324
NCI-H647	CTRP2; CCLE	0.3306	5.2285	0.0111	38.9409
HCC44	GDSC2; CTRP2; CCLE	0.3553	4.0535	0.2445	38.2328
HCC1588	CTRP2	0.3808	4.9339	0.1275	38.45
NCI-H2405	GDSC2; CTRP2	0.3907	5.5938	-0.0087	38.7518
NCI-H2196	CTRP2	0.4682	3.5396	0.4174	37.3093
ChaGo-K-1	CTRP2	0.5077	4.1694	0.3916	37.2419
NCI-H650	GDSC2; CTRP2; CCLE	0.5461	3.7742	0.4781	36.8444
HCC366	GDSC2; CTRP2	0.5566	4.7162	0.3587	37.1548
HCC1833	CTRP2	0.7101	4.3653	0.5805	35.945
NCI-H226	GDSC2; CTRP2; CCLE	0.7172	6.9506	-0.0398	37.5674
NCI-H2009	CTRP2; CCLE	0.7214	12.8478	-2.4059	41.4737
Sq-1	CTRP2; CCLE	0.7402	2.9994	0.7284	35.376
NCI-H1648	CCLE	0.753	2.6515	0.6334	19.8292
NCI-H3255	GDSC2; CCLE	0.8202	4.1052	0.2489	21.3837
Lu-139	GDSC2	0.8291	8.3668	-2.4548	25.5901
NCI-H250	GDSC2	0.8334	5.4309	-0.9954	18.4071
Ms-1	GDSC2	0.8634	4.4043	-0.4634	15.1795
NCI-H1650	GDSC2; CTRP2; CCLE	0.8835	4.401	0.7609	34.7763
NCI-H838	CTRP2	0.9584	2.9165	0.9525	33.9032
NCI-H841	GDSC2; CTRP2	0.9635	6.1127	0.4807	35.3164
NCI-H2818	GDSC2	0.9997	5.9402	-1.0978	18.4221
A-549	GDSC2; CTRP2; CCLE	1.001	5.6341	0.6467	34.7056
RERF-LC-KJ	GDSC2	1.1053	2.0534	0.8871	6.0449
NCI-H1869	GDSC2; CTRP2; CCLE	1.237	3.7	1.2066	32.1287
IA-LM	GDSC2; CTRP2; CCLE	1.2519	7.6395	0.3057	34.7676
Lu-165	GDSC2	1.3349	4.7487	-0.2098	12.0822
NCI-H1395	CTRP2	1.3458	5.4497	1.066	32.2199
NCI-H513	GDSC2	1.4765	7.1266	-1.2768	17.8843
NCI-H889	CTRP2	1.4955	7.7374	0.533	33.3118
NCI-H2444	CTRP2; CCLE	1.4998	4.0027	1.4584	30.4155
T3M-10	CTRP2; CCLE	1.5209	5.1277	1.3245	30.7916
HCC827	GDSC2; CTRP2; CCLE	1.5515	5.2811	1.3265	30.6839
NCI-H2595	GDSC2	1.5769	5.2108	-0.2346	11.5038
NCI-H2731	GDSC2	1.6025	5.1218	-0.1689	11.0219
NCI-H441	GDSC2; CTRP2; CCLE	1.6398	6.6261	1.0669	31.2319
A-427	GDSC2	1.6994	7.4181	-1.2368	16.998
RERF-LC-MS	CTRP2; CCLE	1.7188	5.3443	1.3289	25.1923
HCC4006	CTRP2; CCLE	1.748	4.662	1.6479	28.9602
NCI-H2135	GDSC2	1.7882	5.1402	-0.0262	9.606
NCI-H1435	GDSC2; CTRP2	1.8038	4.2548	1.7551	28.4151
SW900	CCLE	1.8254	3.7826	1.4436	11.9014
MOR/CPR	CTRP2; CCLE	1.8527	3.2837	1.8506	27.9326
NCI-H1963	GDSC2	1.879	4.4584	0.3853	6.7804
NCI-H661	GDSC2; CTRP2; CCLE	1.9182	5.8032	1.6049	28.5543
NCI-H2722	GDSC2	1.953	9.144	-1.8924	19.6021
NCI-H1993	GDSC2	1.9944	4.9854	0.2127	7.5617
NCI-H2803	GDSC2	2.0473	6.4089	-0.4534	11.5186
NCI-H1755	GDSC2; CTRP2	2.0578	4.747	1.967	26.8663
LC-1/sq-SF	CTRP2; CCLE	2.0666	5.3602	1.8692	27.1735
NCI-H2291	CTRP2	2.0816	10.2972	0.1129	32.5468
LK2	CTRP2	2.1475	6.0029	1.8029	27.1449
HCC2935	CTRP2; CCLE	2.1495	9.1137	0.6891	30.7446
HCC2108	CTRP2	2.1699	7.2808	1.4239	28.3671
NCI-H1793	GDSC2; CTRP2; CCLE	2.2469	7.2624	1.5136	27.8261
NCI-H2126	CTRP2	2.2753	4.3719	2.2393	25.2312
NCI-H596	GDSC2	2.3403	5.7936	0.0721	7.5761
HCC95	CTRP2	2.4447	5.1202	2.3242	24.3923
NCI-H1299	GDSC2; CTRP2; CCLE	2.5469	7.9361	1.5844	26.6706
LC-1/sq	GDSC2	2.5812	6.6115	-0.1542	8.3838
UMC-11	GDSC2	2.613	5.9287	0.1987	6.1898
RERF-LC-Ad2	CTRP2	2.615	6.1023	2.2858	23.9932
NCI-H720	GDSC2	2.6527	4.9061	0.7074	3.1115
NCI-H345	GDSC2	2.6672	3.8851	1.1627	0.7383
GLC-82	CCLE	2.6856	6.1776	1.1422	10.8664
NCI-H1373	CTRP2; CCLE	2.7204	6.8214	2.1784	24.0572
VMRC-LCD	GDSC2; CTRP2; CCLE	2.7454	5.7357	2.5235	22.746
SHP-77	GDSC2; CTRP2; CCLE	2.772	4.9734	2.6984	22.0508
NCI-H2369	GDSC2	2.7992	8.1462	-0.747	11.3414
NCI-H2106	CTRP2	2.8132	8.5998	1.5979	25.8389
NCI-H2591	GDSC2	2.834	8.2913	-0.7928	11.5178
NCI-H2869	GDSC2	2.9657	12.4567	-2.7474	20.6422
CAL-12T	CTRP2; CCLE	3.0198	5.5652	2.861	20.6969
LXF 289	GDSC2; CTRP2	3.0405	9.811	1.3082	26.1705
HOP-92	GDSC2; CTRP2	3.0938	12.3119	0.2071	29.3607
CPC-N	GDSC2	3.1836	7.0767	0.0296	6.0282
LCLC-103H	GDSC2; CTRP2; CCLE	3.2331	5.9095	3.0121	19.4982
Hs 229.T	CCLE	3.3419	8.8376	0.361	13.2937
NCI-H1792	GDSC2; CTRP2; CCLE	3.4377	7.8298	2.5709	20.537
NCI-H1573	CCLE	3.5122	6.2818	1.7639	5.5254
LK-2	GDSC2	3.6026	14.0758	-3.0691	20.3718
NCI-H196	GDSC2; CTRP2	4.1128	12.315	1.183	23.7583
NCI-H1355	GDSC2; CTRP2; CCLE	4.1742	9.5901	2.5452	18.6873
HCC2279	CTRP2	4.283	7.5252	3.5837	14.3362
HCC1195	CTRP2	4.3915	15.1102	0.0698	26.4599
NCI-H2085	GDSC2; CTRP2; CCLE	4.4085	9.2323	2.9432	16.5464
NCI-H727	GDSC2; CTRP2; CCLE	4.4241	9.604	2.7831	17.1402
NCI-H2172	CTRP2; CCLE	4.4433	6.0542	4.2944	11.188
NCI-H1563	GDSC2; CTRP2; CCLE	4.894	9.9342	3.0737	14.8641
RERF-LC-Ad1	CTRP2	5.0536	10.1315	3.126	14.2881
HCC1171	CTRP2	5.3057	15.7616	0.5573	22.989
EKVX	GDSC2; CTRP2	5.4512	10.967	3.0728	13.6314
Calu-1	CTRP2; CCLE	5.6672	16.0937	0.702	21.7792
NCI-H2342	CTRP2	5.6676	11.4843	2.328	10.9286
BEN	CTRP2	6.0798	7.8313	5.1803	3.5645
Hs 888.Lu	CTRP2	3.132	10.8337	0.9355	27.1185

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC2	-0.0933	3.8786	-1.1461	22.6984

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
H-STS	CTRP2	-4.0348	-3.0856	-4.0348	67.1487
SYO-1	CTRP2	-3.899	3.3904	-4.2148	62.9783
P-STS	CTRP2	-3.3356	1.0787	-3.3729	61.8275

Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	-1.6863	4.891	-2.1077	51.2764
OC 314	CTRP2; CCLE	-4.1766	-2.9324	-4.1766	68.0929
ES-2	GDSC2; CCLE	-3.5952	-1.8116	-3.5956	56.629
TOV-112D	GDSC2; CTRP2; CCLE	-2.6817	-0.431	-2.6821	58.1208
A2780	GDSC2; CTRP2; CCLE	-2.5834	2.1633	-2.6616	57.0114
COV434	CTRP2	-2.1753	2.8483	-2.2975	54.4112
TYK-nu	GDSC2; CTRP2; CCLE	-1.917	2.0888	-1.9627	52.9415
OAW42	GDSC2; CTRP2	-1.8084	1.6478	-1.8297	52.2775
TOV-21G	GDSC2; CCLE	-1.7422	2.4269	-2.0309	41.5905
OV7	CTRP2	-1.6934	4.2546	-1.9874	51.3674
OC 315	CCLE	-1.6889	-0.3722	-1.6894	40.2715
OC 316	CCLE	-1.5766	-0.4782	-1.5767	39.3053
OV56	GDSC2	-1.5445	2.5882	-2.1487	34.1867
ES2	CTRP2	-0.6544	1.9812	-0.6633	44.6502
DOV13	GDSC2; CTRP2; CCLE	-0.4688	4.0658	-0.6376	43.7434
HEY A8	CTRP2; CCLE	-0.4484	3.5648	-0.55	43.4848
OVTOKO	GDSC2; CTRP2; CCLE	-0.1744	2.4839	-0.1885	41.4722
Caov-3	CTRP2	-0.1346	9.1573	-1.7464	43.7523
JHOC-5	CTRP2	-0.122	2.5505	-0.1372	41.1267
OVCAR-5	GDSC2; CTRP2	-0.0162	3.7713	-0.1158	40.6495
MCAS	CTRP2; CCLE	-0.0089	3.8718	-0.1201	40.6306
SNU-119	CTRP2	0.0845	2.1913	0.0807	39.7179
JHOS-4	CCLE	0.1141	5.0941	-0.8936	29.1847
EFO-21	GDSC2; CTRP2; CCLE	0.35	5.6104	-0.0572	39.0286
EFO-27	GDSC2; CTRP2; CCLE	0.4124	2.87	0.3979	37.5678
IGROV-1	GDSC2; CTRP2; CCLE	0.5886	4.7038	0.3954	36.9317
OVK18	GDSC2; CTRP2	0.7051	6.2509	0.1598	37.125
COV362	CTRP2	0.7537	9.0556	-0.7608	38.9425
ONCO-DG-1	CTRP2; CCLE	0.799	4.6669	0.6287	35.4808
OVCAR-8	GDSC2; CTRP2; CCLE	0.9057	3.8443	0.8496	34.4181
OVCAR-3	GDSC2; CCLE	0.9161	3.5309	0.5615	19.5294
JHOS-2	CTRP2; CCLE	1.0967	5.9677	0.6655	34.3114
OVMANA	CCLE	1.1499	2.6491	1.0648	16.2658
COV318	CCLE	1.188	5.3026	0.1294	20.6577
COV504	CCLE	1.23	3.4965	0.9132	16.6649
SK-OV-3	GDSC2; CTRP2; CCLE	1.4577	6.4443	0.9241	32.2866
OV-90	GDSC2; CTRP2; CCLE	1.4674	6.4352	0.6888	28.389
OVISE	GDSC2; CTRP2	1.6046	2.5961	1.6046	29.5784
OAW28	GDSC2; CTRP2	1.8017	7.3585	0.9989	30.9141
FU-OV-1	CTRP2; CCLE	1.8363	6.7916	1.2281	30.0727
JHOM-1	CTRP2	1.8367	5.3254	1.6268	28.7428
OVCAR-4	GDSC2; CTRP2; CCLE	1.8849	3.5443	1.8788	27.7317
OVSAHO	CTRP2; CCLE	2.5162	5.7501	2.2701	24.3552
SNU-8	CTRP2	2.5365	4.8766	2.4602	23.6287
COV644	CTRP2	2.5369	5.5494	2.3394	24.047
RMG-I	CTRP2	3.1334	8.5992	1.9324	23.7448
SNU-840	CTRP2	3.2828	5.2153	3.2097	18.6468
Kuramochi	GDSC2; CTRP2; CCLE	4.0088	8.2348	2.995	17.3635

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Aska-SS	CTRP2	-0.9874	5.4964	-1.4872	47.3078
Yamato-SS	CTRP2	0.8667	8.0098	-0.2429	37.477
EW-8	GDSC2	-3.9489	-1.6318	-3.96	55.4314
GCT	GDSC2; CTRP2; CCLE	-3.9162	0.9158	-3.9631	65.111
SW872	GDSC2	-3.6455	0.4512	-3.8584	52.1657
TE 617.T	CTRP2; CCLE	-3.4526	-0.8972	-3.4532	63.2049
TE 441.T	CTRP2	-3.0427	2.0412	-3.1321	59.6921
G-402	GDSC2; CTRP2; CCLE	-2.4512	2.9375	-2.6001	55.9939
TTC-709	CTRP2	-2.1631	4.5193	-2.5472	53.9433
KYM-1	GDSC2; CTRP2; CCLE	-2.1263	1.8554	-2.1658	54.2926
G-401	GDSC2; CTRP2; CCLE	-1.9831	2.1208	-2.0332	53.3558
Hs 729.T	CTRP2; CCLE	-1.6644	2.9225	-1.7659	51.2847
SK-LMS-1	GDSC2; CTRP2; CCLE	-1.3523	6.1029	-2.0439	49.4204
MES-SA	GDSC2; CTRP2; CCLE	-1.3012	1.9495	-1.3217	48.9506
A-204	GDSC2; CTRP2; CCLE	-1.1419	3.8023	-1.3193	48.0223
VA-ES-BJ	GDSC2	-0.8343	2.109	-1.2149	26.2744
HT-1080	GDSC2; CTRP2; CCLE	-0.7084	3.8446	-0.8618	45.2541
Rh41	GDSC2; CTRP2	-0.3392	2.467	-0.3563	42.5759
BT-16	CTRP2	-0.1085	2.9715	-0.1429	41.0901
RD	GDSC2; CTRP2; CCLE	0.2761	5.9939	-0.237	39.7323
Rh30	GDSC2; CCLE	0.2985	3.1206	0.0179	24.4613
SK-UT-1	GDSC2; CTRP2	0.8939	6.3653	0.3327	35.9743
Tm87-16	CTRP2	1.0467	6.4936	0.4613	35.0719
RKN	GDSC2; CTRP2; CCLE	1.2146	3.6599	1.1859	32.2723
Rh18	CTRP2	1.3721	5.2108	1.1465	31.872
BT-12	CTRP2	1.7432	3.3593	1.739	28.669
SW982	GDSC2; CTRP2	2.2479	10.184	0.3333	31.4504
SW684	GDSC2	2.3121	7.4929	-0.787	12.78

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	3.268	7.2662	2.611	20.8672

Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IST-Mes2	CCLE	-4.4549	-3.1391	-4.4549	64.0198
MSTO-211H	GDSC2; CTRP2; CCLE	-2.2224	2.0662	-2.2781	54.857
NCI-H2452	CTRP2; CCLE	-2.0318	7.4963	-3.2047	52.6577
NCI-H2052	GDSC2; CTRP2; CCLE	-1.3996	3.7874	-1.5932	49.6258
IST-Mes1	GDSC2; CTRP2; CCLE	-0.4221	4.9473	-0.7463	43.7101
NCI-H28	GDSC2; CTRP2; CCLE	0.2137	2.9721	0.1898	38.9193
MPP 89	GDSC2; CTRP2; CCLE	1.0649	4.4694	0.9451	33.5651
JL-1	CTRP2	2.8283	7.6603	1.991	24.4108
ACC-MESO-1	CTRP2	6.4508	10.8311	3.9807	7.9153

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
22Rv1	GDSC2; CTRP2; CCLE	-2.3292	2.3679	-2.4127	55.4422
LNCaP clone FGC	GDSC2; CTRP2	-2.1217	2.9983	-2.2577	54.0614
DU145	GDSC2; CTRP2; CCLE	-0.4016	2.5314	-0.4228	43.0007
PC-3	GDSC2; CCLE	0.0587	4.1232	-0.574	28.0654
PaCa-3	CTRP2	0.9366	5.9081	0.5067	35.3405
VCaP	GDSC2; CTRP2	1.4076	4.2412	1.3387	31.1206

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	-2.5914	-1.7968	-2.5914	57.5326
A-253	GDSC2; CTRP2; CCLE	-2.5835	0.9164	-2.5976	57.3359

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC2	-1.4523	2.9987	-2.2001	33.9215

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ECC10	GDSC2; CTRP2	-4.4565	-0.096	-4.4763	68.7275
SNU-601	CTRP2	-3.0639	3.3204	-3.3064	59.1194
RF-48	GDSC2	-2.5692	1.9519	-3.0539	43.0716
SNU-1	GDSC2; CTRP2; CCLE	-2.523	1.4379	-2.5538	56.8482
NUGC-3	GDSC2; CTRP2; CCLE	-2.2352	0.2292	-2.2366	55.1461
SNU-16	CCLE	-2.1573	1.2719	-2.2679	44.5668
AZ-521	CCLE	-2.1217	1.454	-2.2559	44.3229
GSS	CTRP2	-1.4705	2.1954	-1.507	50.0638
OCUM-1	GDSC2; CTRP2; CCLE	-1.4187	2.4586	-1.4694	49.7282
SNU-5	GDSC2; CTRP2	-1.397	-0.0003	-1.397	49.5757
ECC12	CTRP2	-1.0413	0.5635	-1.0414	47.2062
23132/87	GDSC2; CTRP2	-0.988	2.9051	-1.0537	46.9416
HuG1-N	CTRP2	-0.9502	6.546	-1.7317	47.2797
NCI-N87	GDSC2; CTRP2; CCLE	-0.938	2.8055	-0.9937	46.6032
RERF-GC-1B	GDSC2; CCLE	-0.7446	3.4113	-1.2059	34.0133
NUGC-4	GDSC2; CTRP2; CCLE	-0.7108	2.7571	-0.7539	45.0928
SNU-620	CTRP2	-0.4703	2.9132	-0.5145	43.5091
MKN7	CTRP2; CCLE	-0.3036	6.1112	-0.9018	43.4098
GCIY	GDSC2; CCLE	0.0776	3.3086	-0.2786	26.6866
LMSU	CTRP2	0.2192	6.7368	-0.5145	40.5293
SK-GT-2	GDSC2	0.5178	2.8288	-0.0557	13.9719
Hs 746.T	GDSC2; CTRP2; CCLE	0.5499	6.7732	-0.1657	38.4943
MKN74	CTRP2; CCLE	0.7256	3.8969	0.6549	35.6614
IM95	GDSC2; CTRP2; CCLE	0.88	6.0778	0.3991	35.8455
SNU-719	CTRP2	0.8879	6.0525	0.4148	35.7736
HGC-27	GDSC2; CTRP2; CCLE	1.0016	8.1224	-0.1392	36.7543
MKN45	GDSC2; CTRP2; CCLE	1.1829	5.7306	0.8212	33.5433
SH-10-TC	CTRP2; CCLE	1.3109	3.0696	1.3066	31.5496
SNU-216	CTRP2	1.315	5.3534	1.054	32.3625
AGS	GDSC2; CTRP2	1.5153	4.4727	1.4253	30.4748
Fu97	CTRP2; CCLE	1.5763	3.5417	1.5643	29.8073
BGC-823	CCLE	1.7085	4.7651	0.8983	15.0636
MKN28	GDSC2	1.7868	4.8849	0.1	8.821
KATO III	GDSC2; CTRP2	2.5613	5.1374	2.4469	23.5947
MKN1	GDSC2; CTRP2	2.794	14.6602	-1.2015	33.5091
SNU-668	CTRP2	3.2403	8.9225	1.9044	23.5466
KE-39	CTRP2; CCLE	3.494	11.7139	0.8795	26.3158
GSU	CTRP2	4.1638	5.2564	4.1417	12.6033
SNU-685	CTRP2	-2.1307	3.489	-2.3318	54.0084
SNG-M	GDSC2; CTRP2; CCLE	0.8356	4.0037	0.7598	34.9469
SNU-1077	CTRP2	7.3711	12.1407	4.0186	6.262

Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ML-1 [Human leukemia]	CTRP2	-3.4831	5.0483	-4.0991	59.9665
FTC-133	GDSC2; CTRP2	-3.3809	0.3916	-3.395	62.4058
IHH-4	GDSC2	-2.5184	-0.3922	-2.5459	41.2938
CAL-62	GDSC2; CTRP2	-2.4807	2.3253	-2.5677	56.3554
8505C	GDSC2; CTRP2; CCLE	-2.4043	0.8666	-2.4145	56.2005
FTC-238	CTRP2	-2.3909	0.7343	-2.3985	56.1298
SW579	CTRP2; CCLE	-1.8395	0.3917	-1.8403	52.5204
CGTH-W-1	CTRP2	-1.8283	1.3002	-1.8396	52.4239
TT2609-C02	GDSC2; CTRP2; CCLE	-1.7733	2.8568	-1.874	51.9672
ASH-3	GDSC2	-0.9577	2.3983	-1.4479	28.0536
B-CPAP	GDSC2; CTRP2; CCLE	-0.4483	3.5238	-0.5452	43.4746
BHT-101	GDSC2; CTRP2	0.4148	4.8028	0.1897	38.1553
8305C	GDSC2; CTRP2; CCLE	0.7422	3.7518	0.6863	35.5044
K5	GDSC2	0.7993	3.615	-0.1413	13.4407
HTC-C3	GDSC2	1.3388	4.8557	-0.2598	12.3791
TT	CTRP2	1.6038	2.7434	1.6036	29.5849
WRO	GDSC2	3.1302	11.421	-2.1122	17.5299

Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
FaDu	GDSC2; CTRP2; CCLE	-3.4503	-0.446	-3.4529	63.1038
CAL-33	GDSC2; CTRP2	-2.9054	1.1568	-2.9344	59.2662
HSC-4	GDSC2; CTRP2	-2.8314	0.2974	-2.8369	59.0233
SAS	GDSC2	-2.6945	-1.2227	-2.6968	42.9549
PE/CA-PJ49	CTRP2	-2.6106	0.15	-2.6132	57.6166
PE/CA-PJ15	CTRP2	-2.6031	2.1802	-2.6836	57.1218
CAL-27	GDSC2; CTRP2; CCLE	-2.4199	0.3033	-2.4226	56.3575
HO-1-N-1	GDSC2	-1.9117	0.4792	-1.9958	35.4908
HSC-2	GDSC2; CTRP2; CCLE	-1.6029	1.8111	-1.6254	50.9327
BICR 22	GDSC2; CTRP2	-1.4404	2.3164	-1.4828	49.8682
PE/CA-PJ34 (clone C12)	CTRP2	-1.368	2.0472	-1.3942	49.3923
BICR 56	CTRP2	-1.2783	2.4019	-1.3201	48.812
PE/CA-PJ41 (clone D2)	CTRP2	-1.1463	3.6479	-1.3022	48.0358
BICR 6	CTRP2	-1.1095	3.5235	-1.2467	47.7904
PCI-04B	GDSC2	-1.0414	1.4778	-1.2528	27.4464
HSC-3	GDSC2; CTRP2	-0.9522	3.3118	-1.055	46.7529
SCC-4	GDSC2; CTRP2	-0.8903	2.6675	-0.9344	46.2745
Ca9-22	GDSC2	-0.7367	2.5965	-1.2824	26.1825
JHU-022	GDSC2	-0.7079	3.6671	-1.6836	28.079
SCC-25	CTRP2; CCLE	-0.6558	2.97	-0.7117	44.7543
SKN-3	GDSC2	-0.568	3.9224	-1.6493	27.2963
OSC-20	GDSC2	-0.4841	4.5885	-1.8617	27.9462
YD-10B	CTRP2	-0.4462	3.451	-0.5352	43.4449
SCC-15	GDSC2	0.064	4.5743	-1.3104	22.9586
BHY	CTRP2	0.1237	3.8097	0.0281	39.718
SCC-9	GDSC2; CTRP2; CCLE	0.6508	7.0377	-0.1402	38.0508
Detroit 562	GDSC2; CTRP2; CCLE	0.6721	5.3759	0.3495	36.7489
UPCI-SCC-090	GDSC2	0.7248	6.3086	-1.5271	21.6565
BICR 10	GDSC2	0.7526	6.4997	-1.5964	21.9138
SNU-1076	CTRP2	0.7912	3.8547	0.7282	35.2015
BICR 78	GDSC2	0.8221	6.1795	-1.3754	20.5307
DOK	GDSC2	0.8909	6.3006	-1.3737	20.2874
Hs 840.T	CCLE	1.0719	7.8131	-1.1556	26.7355
SNU-1066	CTRP2	1.3095	4.5555	1.1943	31.9266
SNU-899	CTRP2	1.4164	4.7148	1.2847	31.2708
SNU-1214	CTRP2	1.4511	3.4091	1.4408	30.6355
SNU-46	CTRP2	1.8588	6.8312	1.2397	29.9622
BB49-HNC	GDSC2	1.9513	9.5396	-2.0913	20.5351
BICR 16	CTRP2	1.9717	4.7733	1.8712	27.4725
NCI-H3118	GDSC2	2.0891	8.2845	-1.3545	16.5138
BICR 18	CTRP2	2.1179	5.6817	1.8526	27.0669
SAT [Human HNSCC]	GDSC2	2.136	6.4818	-0.4208	11.0876
BICR 31	CTRP2	2.1781	6.7241	1.6216	27.673
LB771-HNC	GDSC2	3.3496	8.3724	-0.4748	8.5797
YD-8	CTRP2	3.7855	9.2928	2.2954	20.6369
SNU-1041	CTRP2	4.3016	8.9173	2.984	16.6516

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
647V	GDSC2; CTRP2	-4.3483	-0.995	-4.3516	68.7668
639V	GDSC2; CTRP2; CCLE	-3.3752	-1.7568	-3.3752	62.7519
CAL-29	GDSC2; CTRP2	-2.5841	1.2887	-2.6103	57.2618
T24	CTRP2; CCLE	-2.1317	1.8468	-2.1708	54.3276
5637	GDSC2; CTRP2; CCLE	-1.7807	1.2793	-1.7908	52.1127
J82	GDSC2; CTRP2; CCLE	-1.4865	1.8369	-1.5072	50.1696
UM-UC-1	CTRP2	-1.0995	3.1267	-1.1911	47.6895
BFTC-905	GDSC2; CTRP2	-1.0552	7.3634	-2.1002	47.9672
U-BLC1	CTRP2	-1.0247	5.6658	-1.5703	47.5517
JMSU-1	CTRP2; CCLE	-1.0231	2.1286	-1.0438	47.1164
UM-UC-3	CTRP2; CCLE	-0.6243	0.834	-0.6244	44.4281
SCaBER	CTRP2; CCLE	-0.1769	3.9734	-0.3121	41.7861
RT-4	GDSC2; CTRP2; CCLE	-0.1289	2.3009	-0.1372	41.1526
TCCSUP	GDSC2; CTRP2; CCLE	-0.0145	3.6931	-0.1051	40.6152
SW780	GDSC2; CCLE	0.0356	3.0362	-0.245	26.7053
KMBC-2	CTRP2; CCLE	0.3411	3.9073	0.2472	38.2786
RT-112	GDSC2; CTRP2; CCLE	0.497	2.7914	0.4868	36.9909
KU-19-19	GDSC2; CTRP2	0.7148	3.6645	0.665	35.6675
VM-CUB-1	CTRP2	0.7268	5.2291	0.4417	36.2893
253J-BV	CTRP2	0.9839	8.713	-0.3821	37.3571
BC-3C	CTRP2	2.8531	7.6449	2.0234	24.2218
HT-1197	GDSC2; CTRP2; CCLE	3.5499	7.3969	2.8622	19.5412
SW1710	GDSC2; CTRP2	4.703	11.4744	2.1439	18.9401
HT-1376	CTRP2; CCLE	5.7959	8.2871	4.7097	6.1088

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ME-180	GDSC2	-3.4287	-1.1494	-3.445	50.307
DoTc2 4510	GDSC2	-2.6503	-0.3803	-2.684	42.6314
BPH-1	GDSC2	-2.5219	0.4075	-2.6391	41.6497
SiSo	GDSC2	-2.1549	1.6124	-2.504	38.9208
HT-3	GDSC2	-2.13	0.1633	-2.1878	37.5479
TC-YIK	GDSC2	-1.9485	-0.3506	-1.9597	35.5139
Ca Ski	GDSC2	-1.618	1.1505	-1.8022	33.0411
PWR-1E	GDSC2	-1.5892	1.0886	-1.7573	32.6789
PEO1	GDSC2	-1.3168	2.5516	-1.89	31.9115
CAL-39	GDSC2	-1.2033	1.481	-1.4302	29.1376
PA-1	GDSC2	-1.162	3.5637	-2.1151	32.1341
NEC8	GDSC2	-0.9884	0.0042	-0.9914	25.8392
DSH1	GDSC2	-0.9696	1.9873	-1.3223	27.4662
SKG-IIIa	GDSC2	-0.9168	5.1003	-2.5298	32.6293
C-33 A	GDSC2	-0.8764	2.7274	-1.4812	27.8442
LB831-BLC	GDSC2	-0.4025	4.5569	-1.7655	27.1487
HEC-1	GDSC2	-0.2394	1.9884	-0.5291	19.8616
MS751	GDSC2	-0.1424	2.5818	-0.6422	20.077
HEY	GDSC2	-0.1283	3.871	-1.1781	23.0146
SW756	GDSC2	0.487	7.0782	-2.1229	25.3491
C-4-I	GDSC2	1.7476	3.9121	0.554	6.0693
SKN	GDSC2	1.8564	5.0779	0.0592	8.886
OVMIU	GDSC2	1.9739	5.0784	0.1509	8.0009
SiHa	GDSC2	2.5471	8.0383	-0.8791	12.703
HeLa	GDSC2; CTRP2	3.7873	6.1465	3.5525	15.862
OVCA420	GDSC2	3.9526	5.6564	1.0294	0.3589

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Topotecan (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Topotecan due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[15]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[16]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Topotecan and Roflumilast.	Asthma [CA23]	[15]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Topotecan due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Topotecan due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Topotecan due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Topotecan due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
ABT-492	DMJFD2I	Minor	Decreased absorption of Topotecan due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[17]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Topotecan due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[16]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[18]
Tucatinib	DMBESUA	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[19]
PF-04449913	DMSB068	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[15]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Topotecan and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[21]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[22]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[16]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Topotecan and Denosumab.	Low bone mass disorder [FB83]	[23]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[24]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[25]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Topotecan and Thalidomide.	Multiple myeloma [2A83]	[26]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Topotecan and Tecfidera.	Multiple sclerosis [8A40]	[27]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Topotecan and Siponimod.	Multiple sclerosis [8A40]	[16]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Topotecan and Fingolimod.	Multiple sclerosis [8A40]	[28]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Topotecan and Ozanimod.	Multiple sclerosis [8A40]	[15]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Topotecan and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[29]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[30]
Lonafarnib	DMGM2Z6	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Lonafarnib.	Premature ageing appearance [LD2B]	[31]
Enzalutamide	DMGL19D	Moderate	Accelerated clearance of Topotecan due to the transporter induction by Enzalutamide.	Prostate cancer [2C82]	[32]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[33]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Topotecan due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[17]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Topotecan and Canakinumab.	Rheumatoid arthritis [FA20]	[34]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Topotecan and Rilonacept.	Rheumatoid arthritis [FA20]	[34]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Topotecan and Golimumab.	Rheumatoid arthritis [FA20]	[35]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Topotecan and Leflunomide.	Rheumatoid arthritis [FA20]	[21]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Topotecan when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[36]
Tedizolid	DMG2SKR	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Tedizolid.	Skin and skin-structure infection [1F28-1G0Z]	[15]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[37]
Eltrombopag	DMOGFIX	Moderate	Decreased clearance of Topotecan due to the transporter inhibition by Eltrombopag.	Thrombocytopenia [3B64]	[38]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Topotecan and Valganciclovir.	Virus infection [1A24-1D9Z]	[16]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrochloric acid	E00015	313	Acidulant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Eisenoxyd	E00585	56841934	Colorant
Gelatin	E00630	Not Available	Other agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Tartaric acid	E00029	875	Acidulant; Complexing agent; Flavoring agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Haematite red	E00236	14833	Colorant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Topotecan 0.25 mg capsule	0.25 mg	Oral Capsule	Oral
Topotecan 1 mg capsule	1 mg	Oral Capsule	Oral
Topotecan Hydrochloride eq 0.25mg base capsule	eq 0.25mg base	Capsule	Oral
Topotecan Hydrochloride eq 4mg base/vial injectable	eq 4mg base/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Topotecan FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7101).
• [3] Plant-derived compounds in clinical trials. Drug Discov Today. 2008 Feb;13(3-4):161-71.
• [4] ClinicalTrials.gov (NCT00765973) Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors. U.S. National Institutes of Health.
• [5] BDDCS applied to over 900 drugs
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [9] Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab. 2006 Jan;7(1):105-18.
• [10] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [11] Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
• [12] Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C. Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8.
• [13] Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res. 2008 Nov;25(11):2601-12.
• [14] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [15] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [16] Cerner Multum, Inc. "Australian Product Information.".
• [17] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [18] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [19] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [20] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [21] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [22] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [23] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [24] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [25] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [26] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [27] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [28] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [29] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [30] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [31] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [32] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [33] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [34] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [35] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [36] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [37] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [38] Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]